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ABSTRACT 
Living with a rheumatic disease, such as systemic lupus erythematosus (SLE), can pose many 
challenges. SLE is commonly considered to be a chronic disease, often occurring in 
unpredictable flares with alternating low and high disease activity. The disease predominantly 
affects women, but incidence and prevalence differ across different populations. SLE may 
potentially affect most organ systems with corresponding subjective symptoms, as well as 
objective signs. In general, pain is a commonly reported symptom in patients with SLE. 
Other common symptoms are fatigue, anxiety and depression. Patients with SLE are also 
reported to have a poorer health-related quality of life (HRQoL) compared to the general 
population. All these factors constitute a potential risk for impairment of health as well as a 
negative impact on daily life. Even though there is no cure for SLE, modified treatment 
regimens and new, potentially active drugs have been developed in recent decades. However, 
previous studies have shown that patients consider SLE-related pain not to be sufficiently 
addressed by healthcare providers. Even considering modified treatment regimens, the 
heterogenous nature of SLE, as well as new findings on pain mechanisms, the question of 
whether SLE-related pain is still common and constitutes a health barrier remains 
unanswered. As far as we know, no studies have been conducted in recent years in which 
HRQoL, fatigue, anxiety, and depression have been investigated from a pain and degree of 
pain perspective. More detailed knowledge on extent, intensity and characteristics is therefore 
required. In addition, the chronic course of SLE underlines the importance of investigating 
how SLE-related pain varies over time, and the patient’s experience of how healthcare 
providers address SLE-related pain. 
Aim: The aims of this thesis were to explore to what extent patients with SLE report disease-
related pain and how pain relates to HRQoL, fatigue, anxiety and depression, as well as to 
disease duration, disease activity and damage. The aim also included investigation of how the 
pain varies over time and impacts on daily life. 
Method: Data were collected from two cross-sectional cohort studies at inclusion (year 0) 
and seven-year follow up (year 7). At year 0, 84 patients with SLE and 91 age- and sex-
matched controls from the general population completed self-assessment measures and 
questionnaires on pain using the Visual Analogue Scale (VAS) and the short-form McGill 
Pain Questionnaire (SF-MPQ); fatigue using the Multidimensional Assessment of Fatigue 
(MAF); HRQoL using the Medical Outcomes Survey-Short Form 36 (SF-36); and anxiety 
and depression using the Hospital Anxiety and Depression Scale (HADS). These assessments 
and questionnaires were completed again at year 7, when 64 of 84 patients with SLE and 68 
of 91 gender- and age-matched controls from the inclusion cohort participated. In addition, 
  
data on age, disease duration, disease activity and damage, as well as treatment with 
glucocorticoids were collected at both years 0 and 7. At year 7, data collection was 
supplemented with assessment of pain-related problems (VAS), data on pain duration, a pain 
drawing, and data on analgesics. At year 0, the patients were dichotomized into two groups 
designated the low-pain group and the high-pain group based on their SLE-related pain 
intensity score using VAS. A cut-off value, 40 millimetres, was chosen based on the 
distribution of scores using VAS. The division into the low-pain group and the high-pain 
group at year 0 was used for intra-group comparisons of collected data at both year 0 and year 
7. 
A qualitative approach was applied to investigate the impact of SLE-related pain on health 
and daily life, as well as the patient’s expectations of healthcare providers. Twenty patients 
from two cohorts in the same urban region, south and north, participated in an interview 
study. The recorded interviews were based on an interview guide and transcribed verbatim. 
Thereafter, the text was analysed using qualitative content analysis. 
Results: At year 0, the patients in the high-pain group constituted 24% of the SLE cohort and 
were characterized by significantly shorter disease duration and higher disease activity 
compared to the patients in the low-pain group. The patients in the high-pain group used 
significantly more descriptive words compared to the patients in the low-pain group when 
scoring their pain intensity using SF-MPQ. They also reported significantly lower HRQoL 
and scored higher levels of fatigue, anxiety and depression compared to the patients in the 
low-pain group and the controls. However, the low-pain group did not differ significantly 
from the controls regarding reported pain, fatigue, anxiety and depression. Treatment with 
glucocorticoids did not differ between the pain subgroups, and patients treated or not treated 
with glucocorticoids did not differ when scoring pain intensity. At follow-up in year 7, the 
high-pain group scored significantly lower levels of SLE-related pain using VAS. However, 
only half of the patients in the high-pain group scored a lower pain intensity while the other 
half had an unchanged pain score level from year 0. These patients with remaining high pain 
level scored statistically similar levels for HRQoL (except for a poorer score for the 
dimension vitality), as well as for fatigue, anxiety and depression as year 0, and significantly 
poorer scores in all self-reported assessments except for anxiety (HADS) and mental health 
(SF-36), compared to the patients with decreased pain, the low-pain group and the controls at 
year 7. Conversely, the patients with decreased pain scored significant improvements in all 
self-reported assessments. The patients in the low-pain group scored statistically similar 
levels for pain, most dimensions of HRQoL (SF-36), as well as for fatigue, anxiety and 
depression at year 7 as at year 0. Further, the patients in the low-pain group scored mainly 
  
statistically similar levels as the controls and the patients with decreased pain at year 7.  
In the interview study, the informants delineated their disease-related pain as long-standing, 
unpredictable and migratory. They also depicted a high symptom burden from their disease-
related pain on health and daily life. The informants used several strategies to deal with pain, 
mainly through adaption and by finding new ways to perform different tasks and to maintain 
their roles in relation to others. They expected their pain to be acknowledged and to be met 
well by the healthcare providers. Furthermore, interventions against pain which were not 
dependent on economic prerequisites, and individual tailored advice and information were 
also requested. 
Conclusion: Taken together, the results from these studies revealed that severe SLE-related 
pain (≥40 mm on VAS) is present in a minority of the patients with SLE. Furthermore, the 
pain intensity tended to decrease over time. Despite that, the patients with remaining severe 
pain reported a high symptom burden with impaired HRQoL, more fatigue, anxiety and 
depression, even though mental health appeared to be less affected. In spite of the fact that 
patients with severe pain use several strategies to deal with pain, individual adapted 
interventions designed to alleviate pain and support for the patients are strongly needed from 
healthcare providers. Moreover, acknowledgement of SLE-related pain is crucial. 
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1 FOREWORD 
Taking part of patients’ experiences of pain from different rheumatological diseases, in 
particular patients with systemic lupus erythematosus (SLE), is common in my long career as 
a nurse in rheumatology care. Gratifyingly, pharmacological advances in recent decades have 
made it possible to reduce disease activity and thereby reduce pain. However, despite these 
advances, some patients still express pain. Interventions and pharmacological treatments to 
reduce pain are not as well developed as for organ manifestations and, because there is no 
obvious life-threatening organ manifestation, patients with pain are often considered to have a 
mild disease. However, from my perspective as a nurse, for whom health is of central 
importance, SLE-related pain poses a risk of being a health barrier. Due to organizational 
structures and the complex nature of SLE, these patients are also at risk of being passed from 
one healthcare provider to another, which can add to the existing burden of a chronic disease. 
Thus, when an opportunity appeared to further investigate the experience of pain in patients 
with SLE, I wanted to find out whether I could confirm my concerns regarding impaired 
health in patients with SLE-related pain. Furthermore, I wanted to find out what patients with 
SLE-related pain thought they needed to deal with pain. 
Hopefully, the results from this thesis will constitute a base for further research on supporting 
patients in dealing with SLE-related pain, and inspire the establishment of networks between 
healthcare providers for multidisciplinary care and interventions. 
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2 INTRODUCTION 
Living with a chronic disease may pose many challengers for the patient especially in 
diseases with an unpredictable course such as systemic lupus erythematosus (SLE) (1). SLE 
is a systemic autoimmune rheumatic disease potentially affecting most organ systems by 
autoimmune inflammation, and displays a wide range of symptoms and severity depending 
on which organ is affected (2). Due to advances in medical care and treatment over recent 
decades, morbidity and mortality has decreased considerably and, generally, the disease is no 
longer considered life-threatening. However, the disease is still considered to be a chronic 
disease for which there is yet no cure. 
Pain, which is the focus of this thesis, is described as a common and burdensome symptom in 
patients with SLE (3-5), and thereby may constitute a threat to health as defined in the World 
Health Organization (WHO) constitution (6) “health is a state of complete physical, mental, 
and social well-being and not merely the absence of disease or infirmity…” . This definition 
of health originates from 1948 and has later been supplemented to provide a more 
comprehensive definition. Notwithstanding, this original sentence introduces the definition of 
health that is used in this thesis. 
In addition, despite advancement in medical care, reports exist where patients with SLE 
express dissatisfaction with how pain is met by healthcare providers (7, 8). Due to the 
heterogenous nature of SLE, pain may compete with other concomitant symptoms, some of 
which are potentially life-threatening, for example lupus nephritis. Absence of serious 
internal organ involvement may cause the healthcare provider to perceive the disease as mild, 
and to underestimate and trivialize the patient’s experience of pain (8). Moreover, feelings of 
not being understood and not being taken seriously may create a lack of dignity and suffering, 
adding to the already existing burden of a chronic disease (9). 
From a nursing perspective, health is of central importance. For example, health is present in 
the nursing metaparadigm: health, person, environment and nursing (10). Moreover, 
promoting and restoring health are areas of responsibility in nursing according to the 
International Council of Nurses (ICN) (11). Thus, due to the prolonged course of the disease, 
efforts should be made to support patients with SLE and pain to experience health. 
Investigating patients’ experiences of SLE-related pain and how pain affects their lives is of 
crucial importance. The results will contribute to an updated and extended knowledge and 
point out which interventions and further research are needed to support patients with SLE to 
improve and maintain health.  
4 
4 
3 BACKGROUND 
3.1 SYSTEMIC LUPUS ERYTHEMATOSUS AND IMPACT ON LIFE 
Systemic lupus erythematosus (SLE) is a systemic autoimmune rheumatic disease 
characterized by changes in the immune system and expression of autoantibodies mainly 
against components in the nucleus, such as the antinuclear antibodies (ANA), which include 
subgroups even more specific for SLE. Typically, the disease has a flare pattern with periods 
of low disease activity which switch to periods of high disease activity. The cause of the 
disease is not yet fully understood, but it is known that both genetics as well as environmental 
factors contribute to the development of the disease. Exposure to UV light is a well-known 
environmental factor, but virus infections and pharmaceuticals are also suspected to be 
triggering factors (12). The disease is considered rather uncommon, and prevalence and 
incidence vary between studies and populations. The estimated annual incidence rate for 
Europe is between 1 and 4.9 per 100,000 and the annual worldwide incidence rate ranges 
from 1 to 8.7 per 100,000. The prevalence in Europe ranges from 28 to 97 per 100,000 and 
worldwide from 28.3 to 149.5 per 100 000 (2, 13, 14). SLE is more common in females than 
men in an approximate 9:1 ratio, which suggests female hormones could be triggers for 
developing the disease (2). 
Commonly affected organs are the joints and the skin but basically all organs can be affected 
by the inflammation. Feared manifestations include inflammation in the central nervous 
system and nephritis. The severity of the disease varies widely from very mild to severe. The 
disease was previously considered to be life-threating, but newer treatment regimens and 
pharmaceuticals have resulted in decreased morbidity and mortality. However, mortality is 
still higher compared to the general population, and is also associated with a higher risk of 
cardiovascular disease (2). 
In addition to organ-specific symptoms, common patient-reported symptoms are fatigue, 
pain, malaise and fever (2). 
Disease-specific criteria have been developed to identify patients with SLE, especially in 
research settings. The first criteria were developed in 1971 by the American College of 
Rheumatology (ACR) and were revised in 1982 and 1997. The most recent version of the 
criteria was developed in 2012 by the Systemic Lupus International Collaborating Clinics 
(SLICC). The revised versions reflect the difficulty in comprehending the heterogenous 
nature of SLE, as well as new knowledge in immunology and new understanding of the 
results of serological tests (15). The criteria from 1982 from the American College of 
5 
 5 
Rheumatology (ACR) have been validated and are commonly used (16). To meet these 
criteria in a research setting, four out of eleven criteria must be met (Table 1). 
 
Similarly to other patient groups with longstanding diseases, patients with SLE must deal 
with many challenges, and are at risk of a negative impact on daily life and health. However, 
SLE can exhibit varying degrees of symptoms and severity, and thus affect individuals in 
very different ways. In general, earlier studies showed poorer health-related quality of life, 
more fatigue and pain as well as more symptoms of anxiety and depression in patients with 
SLE compared to controls (2, 17-21). Moreover, earlier studies showed a negative impact on 
various aspects of life for patients with SLE such as difficulties in relationships with family, 
spouses and others, impaired working ability in and outside the home, with a consequent 
negative economic impact, and negative self-perception (22-26). Pharmacological treatment 
to reduce disease activity, which comprises immunosuppressive drugs including 
glucocorticoids and biologics (2), offers opportunities but can also lead to patient-reported 
concerns about toxicity and side effects (22). In interview studies (22, 27), patients with SLE 
have described the uncertainty that resulted from the unpredictable course and fluctuating 
activity of the disease. However, the patients who were interviewed also learned to manage 
the disease and its symptoms and found potential in their lives. 
Previous studies have reported mutual relationships between commonly self-reported 
symptoms such as pain, fatigue, anxiety and depression and those symptoms relationship with 
HRQoL (4, 28-31). There are also reports that patients with SLE experience dissatisfaction 
concerning help with these symptoms from healthcare providers (7, 8, 32). 
Table 1. 1982 revised ACR criteria for identification of patients with SLE in clinical studies; 4 or 
more of 11 manifestations should be present (16) 
 
Malar rash 
Discoid rash 
Photosensitivity 
Oral ulcers 
Arthritis 
Serositis 
 
 
Renal disorder 
Neurological disorder 
Haematological disorder 
Immunological disorder 
Antinuclear antibody (ANA) 
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3.2 PAIN 
Pain is a subjective sensation defined by the International Association for the Study of Pain 
(IASP) as “An unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage”(33). The definition highlights 
the complex nature of pain and the multidimensional influence it may have on the individual. 
Nevertheless, pain is not only negative - it is also essential in defending the body against 
potentially threatening inflammation and damage (34).  
Pain can be classified from different perspectives (35): 
x Intensity: mild, moderate and severe pain 
x Duration: acute, long-standing, transient and breakthrough pain 
x Origin: postoperative/post-traumatic pain, cancer-related pain, long-standing pain 
x Aetiology: physiological pain, physiological inflammatory pain, pathological 
inflammatory pain (nociceptive pain) neuropathic pain and somatic pain 
Nociceptive pain is generated by noxious stimulation of nociceptors located in peripheral 
nerve endings in cases of injury and/or inflammation. The nociceptors transmit signals from 
damaged tissue via action potentials to the central nervous system through the dorsal root 
ganglia (36). Neuropathic pain arises from injury or disease in a peripheral or central nerve, 
for instance pain after stroke or postherpetic neuralgia (37). The conscious perception of pain 
emerges through processing pain stimulus in a network of different areas in the brain 
commonly called the pain neuromatrix (34). 
Long-standing pain is defined as pain that persists beyond the expected healing time or more 
than three months (38). The prevalence of long-standing pain in European adults in the 
general population ranges from 19 to 53% (39-41). Chronic widespread pain (CWP) is 
defined by the sub-criteria as a part of the ACR 1990 criteria for fibromyalgia syndrome as 
suggested by Wolf et al. (42), “persistent pain for more than three months and pain in both 
sides of the body, pain over and below the waist and axial pain (cervical and thoracic spine, 
anterior chest pain and low back pain) must be present. In this definition, left or right 
shoulder and buttock pain were considered as pain for each involved side”. 
Persistent pain after expected healing time and pain without any obvious stimulus is 
considered to be a disease in the peripheral and/or central nervous system (34). Central 
sensitization denotes a condition with disturbances in normal pain processing in the central 
nervous system with increased activity in the pain facilitation pathways, together with 
disturbed function in the descending inhibitory pathways and overactivity in the pain 
7 
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neuromatrix. Central sensitization is characterized by generalized hypersensitivity and/or 
allodynia, which refers to pain triggered by stimulus that usually do not trigger pain (43). 
The treatment of pain in different conditions with long-standing pain and persistent pain due 
to central sensitization is primarily multidisciplinary. Non-pharmacological treatment 
constitutes the cornerstone in reducing/alleviating pain in long-standing musculoskeletal pain. 
Studies on non-pharmacological treatments include cognitive behavioural therapy (CBT), 
acceptance and commitment therapy (ACT), physical activity/exercise, patient education (in 
group or individual), as well as complementary alternative medicine (CAM; acupuncture, 
massage, yoga). In addition, pharmacological treatment such as analgesics, antidepressants 
and anticonvulsants may be beneficial. The majority of non-pharmacological treatments 
usually provide beneficial outcomes when used in combination with pharmacological 
treatment (40, 44). 
Pain is a prominent symptom in several rheumatic diseases and current research indicates that 
repeated stimulation of peripheral nociceptors, as in inflammation, may cause functional and 
structural changes in the central nervous system leading to abnormal pain processing, such as 
central sensitization (45, 46). 
3.3 PAIN IN PATIENTS WITH SLE 
Although not all patients with SLE report pain (3), it is a common self-reported symptom, 
and one of the most common symptoms in the early stage of the disease and before diagnosis 
(4, 47, 48).  
The most common locations for SLE-related pain are the musculoskeletal system in terms of 
arthralgia, arthritis and myalgia, but headache and Raynaud’s phenomenon are also 
commonly present (3, 47). During the course of the disease, musculoskeletal pain is reported 
to be present in 50% to 90% of patients with SLE (4, 49). Pain related to SLE has been 
described by the patients as obtrusive and unpredictable, sometimes with a continuous nature 
but also with rapid changes in intensity and location (27). The cause and pathophysiology of 
pain in SLE may vary and is not always evident. Theoretically, pain in SLE can be explained 
by inflammatory, neuropathic and central pain (5). The most common type of pain in SLE is 
reported to be inflammatory (nociceptive) pain, mainly in the joints. Neuropathic pain in SLE 
includes peripheral neuropathic pain in terms of neuropathies and neuropathic pain in the 
central nervous system. The underlying cause of neuropathic pain in the central nervous 
system, with symptoms of headache and neuropsychiatric SLE, remains unclear (49). Central 
pain refers to disturbed pain processing in the central nervous system, usually called central 
8 
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sensitization as described previously (5, 49), which is believed to be the underlying cause of 
chronic widespread pain (CWP). CWP constitutes the core of the criteria for fibromyalgia 
syndrome (42) and is highly prevalent in patients with SLE, range 65% to 80% (49). 
Likewise, concomitant fibromyalgia syndrome is common and, although varying between 
different studies, the prevalence is reported to be 17% to 40% in patients with SLE (47, 50). 
There are several common and overlapping symptoms in SLE and fibromyalgia syndrome 
such as pain and fatigue. These similarities may affect and confound diagnostic assessment 
and lead to under- and over-diagnosis of fibromyalgia syndrome and SLE, respectively (50). 
The similarity between SLE and fibromyalgia syndrome may also impact and confound the 
selection of treatment. Since there are different treatment regimens in different pain 
conditions and in SLE, determining the cause of pain in patients with SLE appears crucial to 
avoid an incorrect diagnosis as well as over- and undertreatment (5).  
Except for pharmacologic analgesia, treatment interventions for SLE-related pain have been 
sparsely investigated. However, there are a few, including a pilot, randomized controlled 
study which demonstrated a beneficial effect of acupuncture (51). Further, an intervention 
study based on a Problem-based learning (PBL) programme was demonstrated to be 
beneficial in improving self-care empowerment in patients with different rheumatic diseases 
and chronic musculoskeletal pain (52). 
Although many patients with SLE cope well with disease-related pain, it has been identified 
by patients to be a health problem (3, 48) where pain impairs HRQoL, reinforces the effect of 
fatigue and has a complex impact on the psychological state (28-31). 
Moreover, pain in SLE may contribute to limitations in daily activities like exercise, 
household chores, gardening, and even occasionally personal hygiene (22, 23, 53-55). SLE-
related pain is also associated with work disability and high absence from work (24).  
Patients with SLE have also expressed dissatisfaction with how pain in SLE is met and 
acknowledged by healthcare providers (7, 32, 56). 
3.4 HEALTH, QUALITY OF LIFE AND HEALTH-RELATED QUALITY OF LIFE 
A common definition of health is that by the WHO (6), “health is a state of complete 
physical, mental, and social well-being and not merely the absence of disease or infirmity..”. 
In addition, health can be seen as a continuum with two extremes, illness and health, where 
the person makes transitions along the continuum (57). To experience health does not 
necessarily exclude disease and disease does not always mean experiencing illness (58). 
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There are several definitions of the concept quality of life (QoL) based on different 
perspectives (59). Although, there is no clear consensus on how to define the concept, there is 
agreement that the concept is multidimensional (60). QoL is frequently used as an outcome 
variable not only in nursing but also in medical, social, economic and behavioural research 
(60). The WHO defines quality of life as “an individual’s perception of their position in life 
in the context of the culture and value systems in which they live and in relation to their 
goals, expectations, standards and concerns. It is a broad-ranging concept affected in a 
complex way by the person’s physical health, psychological state, personal beliefs, social 
relationships and their relationship to salient features of their environment” (61). QoL could 
be difficult to distinguish from the concept health which is also a multidimensional concept 
most commonly defined by the WHO as cited earlier. However, it is deemed that there is a 
clear distinction between the two concepts where the definition of quality of life is broader, 
and the concepts cannot be used interchangeably (62). Smith et al. (62) found in a meta-
analysis that patients considered mental health when rating quality of life but physical 
function when rating health status. However, Plummer and Molzhan (59) found the concepts 
QoL and health so alike and so closely related that they proposed that QoL could replace 
health in the nursing metaparadigm. 
Health-related quality of life denotes QoL in connection with health and narrows the broader 
definition of QoL (63). 
3.5 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SLE 
In earlier reviews, health-related quality of life (HRQoL) in patients with SLE is reported to 
be poorer compared to controls and population norms regardless of measurement and 
population under study. However, studies show that different dimensions of HRQoL seemed 
to be more or less affected by SLE in different studies (17, 18, 64, 65). 
There are conflicting results regarding the relationship between HRQoL, disease activity and 
damage. Nevertheless, most studies found no obvious relationship between HRQoL, disease 
activity and damage (17, 18, 66) which may indicate a complex relationship with influencing 
factors that are difficult to sort out. 
Several factors have been shown to potentially influence HRQoL in patients with SLE; the 
disease itself, treatment and the patient’s ability to cope with the disease. Factors identified to 
promote HRQoL in patients with different rheumatic diseases include support from 
significant others, sleeping well and feeling well-rested, a strong sense of coherence, being 
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young or middle-aged and being able to work (67, 68). In addition, a decrease in SLE-related 
pain and feeling pain-free have been shown to improve HRQoL (67, 69). 
3.6 FATIGUE IN PATIENTS WITH SLE 
Commonly, fatigue is described as uncontrolled, untreatable physical and mental exhaustion, 
not synonymous with tiredness (70). Fatigue is a frequently self-reported symptom in patients 
with rheumatic diseases, particularly in SLE, and is often described as a paramount subjective 
symptom (2, 4, 20, 71). Approximately 53% to 80% of patients with SLE report fatigue as 
one of their primary symptoms (72). SLE-related fatigue is described by patients as 
controlling, unbeatable and beyond words, and fatigue and pain have been reported to 
reinforce each other (28, 71, 72). Fatigue in SLE is reported to have a considerable negative 
impact on several dimensions of daily life such as work, practical daily activities, leisure, 
social and family activities as well as negative emotional and cognitive impacts (73).  
The cause of fatigue in SLE is not clear but likely multifactorial (72) where mechanisms in 
the peripheral and central nervous system contribute (74). Elevated levels of IL-1β in 
cerebrospinal fluid have been found in patients with rheumatoid arthritis compared to 
controls (75), and where elevated levels of IL-1β correlated with assessment of fatigue but 
not with assessment of pain and tender joints (76). Convincing evidence for interventions 
aimed at reducing fatigue in SLE is lacking. However, there are indications that aerobic 
exercise and belimumab may be effective (77). Currently, more knowledge is needed to 
understand and develop further interventions to reduce and alleviate fatigue in SLE and other 
inflammatory diseases. 
Taken together, the great impact of SLE-related fatigue on daily life implies that fatigue can 
be considered as a potential health barrier. 
3.7 ANXIETY AND DEPRESSION IN PATIENTS WITH SLE 
Anxiety and depression are reported to be more prevalent in patients with SLE compared to the 
general population (19, 20), and present in 28% to 65% of the patients (19, 75, 78). However, 
the prevalence varies between studies and probably due to the method and assessment used 
(21). The mechanisms behind these common symptoms as well as other psychiatric and 
neuropsychiatric symptoms in patients with SLE are unclear, but a number of theories exist 
(79). Self-reported disease activity (19) emerged as one of the theories on causes and 
contributing factors, and another theory suggested a reaction to living with an unpredictable 
chronic disease with poor understanding of the disease (80). Kozora et al. (20) found a strong 
correlation between cognitive impairment and depression, pain and fatigue in patients with 
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neuropsychiatric SLE and therefore suggested global changes in the central nervous system. 
Psychiatric symptoms in patients with SLE, especially anxiety and depression, are known 
barriers to having a good HRQoL (18). 
The complex relationship between pain, fatigue, anxiety and depression and the role of pain as 
a barrier to reach health is presented in Figure 1. 
 
 
  
 
     
      
 
      
 
 
 
 
 
Figure 1. The complex relationship between pain, fatigue, anxiety and depression and pain as 
a barrier to reach health 
health 
illness 
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4 RATIONALE FOR THE THESIS AND AIMS 
Over the last decades there have been advances in medical care and pharmacological 
treatment for patients with SLE, leading to decreased morbidity and mortality. In addition, 
there are new insights into pain and pain-processing mechanisms. Despite these advances, 
some previous studies report that pain in SLE is still a common self-reported symptom (4, 8, 
47) and may constitute a threat to health (3, 48). In addition, some studies report a mutual 
relationship between pain and other subjective symptoms such as fatigue, anxiety and 
depression, and that patients with SLE experience that healthcare providers pay insufficient 
attention to these subjective symptoms (7, 8, 32, 56). In respect of these previous studies, 
more detailed knowledge on the occurrence, intensity and characteristics of self-reported 
SLE-related pain is needed. The chronic nature of SLE makes it important to investigate how 
pain varies over time, how pain relates to fatigue, anxiety and depression over time, as well as 
how pain affects HRQoL and different aspects of daily life. Since pain is reported to be a 
common symptom in the general population (39, 40), the studies also investigate whether 
there are any differences in reported pain between patients with SLE and controls from the 
general population. Furthermore, an update is needed on how patients with SLE experience 
how healthcare providers address SLE-related pain, and what they believe they need from 
healthcare providers to better deal with the pain. 
 
The overall aim of this thesis was to explore to what extent patients with SLE report disease-
related pain and how pain influences health and different aspects of life. 
The aim of study I was: 
x to investigate the extent of self-reported SLE-related pain in terms of intensity and 
characteristics 
x to measure disease activity and disease duration in relationship to pain 
The aim of study II was: 
x to investigate overall pain, health-related quality of life, fatigue, anxiety and 
depression in patients with SLE and age- and sex-matched controls from the general 
population 
The aim of study III was: 
x to investigate self-reported SLE-related pain in a seven-year follow-up survey, as well 
as the presence of long-standing widespread pain, health-related quality of life, 
fatigue, anxiety and depression 
13
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The aim of study IV was: 
x to acquire a deeper understanding of what SLE-related pain means to the patients in 
daily life and what support is needed from healthcare providers to deal with SLE-
related pain 
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5 STUDY POPULATION AND METHODS 
Both a quantitative and a qualitative approach were applied in this thesis. Initially, two 
quantitative cross-sectional studies were performed to investigate the existence of pain and its 
connection with HRQoL, fatigue, anxiety and depression (inclusion, year 0). These studies 
were followed by a quantitative cross-sectional seven-year follow-up study (year 7) of the 
same cohort and with patient reported assessments and questionnaires. In addition, a 
qualitative interview study was performed to obtain a deeper insight into the patients’ 
experiences of SLE-related pain and how pain influences daily life, data which are difficult to 
gain through quantitative methods. 
5.1 STUDIES I-II 
The participants in the inclusion study (year 0) were recruited consecutively from an on-
going cohort study, SLEVIC (SLE Vascular Impact Cohort) (81), in which patients with SLE 
according to the 1982 revised ACR criteria (16), aged 18 to 70 years, participated. Potential 
study participants for the cohort study were identified by diagnosis codes in the electronic 
medical record system at the Department of Rheumatology, Karolinska University Hospital, 
Huddinge, Stockholm, Sweden. Identified potential study participants were mailed letters 
with an invitation to participate in the cohort study. They were also invited by telephone and 
in connection with routine visits at the clinic. For comparison, sex- and age-matched controls 
were randomly identified from the general population through the Swedish population 
register. These controls were from the same greater urban area as the patients and were 
invited to participate in the cohort study by mail. 
Over a period of 13 months, from 2006 to 2008, 84 patients and 91 controls from the ongoing 
cohort study were invited to participate in the present inclusion study. All agreed to 
participate. 
5.2 STUDY III 
In the seven-year follow-up study (year 7) performed from 2013 to 2015, it was possible to 
follow 64 (76%) of 84 patients and 68 (75%) of 91 controls recruited from the original 
inclusion study (year 0). Reasons for not participating in the follow-up study for the patients 
were: death (n=4), migration (n=3), unable to participate due to illness other than SLE (n= 2) 
and unwilling to participate (n=11); and for the controls: migration (n=1), unable to 
participate due to illness (n=5) and unwilling to participate (n=17). No significant difference 
in age (years) was found between those patients who participated, median interquartile range 
(IQR) 52 (38.5 to 64) and those who did not, 54.3 (45 to 64.6) (p=0.29), nor for the controls 
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who participated, 56 (46.5 to 66) and those who did not, 49.7 (38.2 to 67.5) (p=0.15). 
Furthermore, there was no significant difference in disease duration (years) among those 
patients who participated, median (IQR) 16 (11.5 to 22.5) and those who did not 16 (13 to 25) 
(p=0.74) in the seven-year follow-up study. 
5.3 STUDY IV 
In connection with the self-assessment questionnaires at the seven-year follow-up study, the 
patients were asked whether they were interested in participating in a subsequent interview 
study on SLE-related pain. The response options were yes, no and maybe. All patients in the 
follow-up study who had ever reported SLE-related pain during the previous week ≥40 mm 
on VAS, either at inclusion or at follow-up or at both, and who had responded yes or maybe 
to the question regarding participation in the interview study, were invited by phone to 
participate in the interview study. Of 20 potential participants, 12 (60%) patients agreed to 
participate. For a suitable sample of informants, another eight participants who had reported 
SLE-related pain during the previous week ≥40 mm on VAS were recruited. This enabled 
patients to participate both from the north and south within the same urban area.  
The studies, designs and populations are summarized in Table 2 and demographics and 
characteristics of the study populations are presented in Table 3.
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6 DATA COLLECTION 
In studies I-III, the participants were invited to respond to self-assessment questionnaires on 
pain, HRQoL, fatigue, anxiety and depression in connection with the inclusion visit in the 
cohort study and the seven-year follow-up visit (Table 2). In addition to the self-assessment 
questionnaires, characteristics such as age, disease duration, disease activity and damage, 
current treatment with glucocorticoids and disease modifying anti-rheumatic drugs 
(DMARD) were collected. At the seven-year follow-up study (study III) the participants were 
also asked to report current use of analgesics if applicable.  
Studies I-III were conducted at an outpatient clinic in the Rheumatology Department at the 
Karolinska University Hospital, Huddinge, Stockholm, Sweden. In Study IV, the interview 
was conducted at a location chosen by the informant. 
6.1 SELF-ASSESSMENTS AND QUESTIONNAIRES 
6.1.1 Pain 
A visual analogue scale (VAS) was used to measure self-reported pain intensity during the 
previous week, (82, 83). The scale consists of a 100 millimetre (mm) long horizontal line 
symbolizing a continuum of increased pain with two extreme endpoints. The beginning of the 
line represents no pain and the end of the line represents worst imaginable pain. The scales 
were connected to the questions how much pain have you experienced on average the last 
week? and for the patients only how much pain due to SLE have you experienced on average 
the last week? The participants estimated their pain during the previous week by placing a 
transverse line on the 100 mm horizontal line. Cut-off values on VAS, e.g. for mild, moderate 
and severe pain, are not fully defined. Common cut-off values on VAS for patients with acute 
pain are 1 to 3 centimetres (cm) for mild pain, 4 to 6 cm for moderate pain and 7 to 10 cm for 
severe pain (84). Boonstra et al. (85) found that ≤3.4 cm best corresponded to mild pain, 3.4 
to 7.4 cm to moderate pain and ≥7.5 cm to severe pain in patients with chronic 
musculoskeletal pain. 
In order to measure the nature of self-reported pain, the short-form McGill Pain 
Questionnaire (SF-MPQ) (86) was also used. This form contains three items. In the first item 
the patients were asked to grade pain intensity (0=none, 1=mild, 2=moderate and 3=severe) 
for fifteen predefined descriptive words. The reported intensity of each descriptive word is 
thereafter summarized in a total index, range 0 to 45, where a higher score indicated more 
pain. Furthermore, the total index enables a score for sensory (0 to 33) and affective (0 to 12) 
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indices. In the second item, the patients were asked to report their current overall pain 
intensity using VAS. In the last and third item, the present pain index (PPI), the patients were 
asked to choose one of six predefined words that most accurately describes their present pain; 
no pain, mild, discomforting, distressing, horrible and excruciating. The form is considered 
to be suitable for use with patients with long-standing pain (84), and has been tested for 
validity and reliability in Swedish patients with fibromyalgia syndrome (87) and in Turkish 
patients with rheumatoid arthritis (88). 
In addition to the VAS and the SF-MPQ, the participants were asked to respond to three 
additional self-assessments at the seven-year follow-up visit (study III); problems related to 
pain on VAS, duration of pain and if applicable a pain drawing (Table 2).  
The VAS (100 mm) was connected to the question to what extent has SLE-related pain been 
a problem for you over the previous week? 
To investigate the presence of CWP, the participants were also asked if their pain had lasted 
more than three months by choosing one of two response options, yes or no. 
Those participants who reported pain lasting more than three months were asked to mark 
painful areas on a pain drawing with predefined body regions (89). 
6.1.2 Health-related quality of life 
To measure HRQoL in patients and controls, the Medical Outcomes Survey-Short Form 36 
(SF-36) Standard Swedish Version 1.0 was used. The SF-36 is a generic instrument to 
measure the multidimensional concept of health in the general population and in other 
populations (90). It has been translated into Swedish and many other languages and cultural 
contexts (90). Although the instrument is generic, it can easily be supplemented with disease 
specific assessments. The SF-36 contains 36 items grouped into eight domains; physical 
functioning, role limitations due to physical problems, bodily pain, general health, vitality, 
social functioning, role limitations due to emotional problems and mental health. Raw scores 
for each domain are transformed to a scale range 0 to100, where 0 represent worst possible 
health state and 100 best possible health state. The psychometric tests of the Swedish version 
of SF-36 showed good validity and reliability (90, 91). The SF-36 has shown good validity 
and reliability in patients with SLE (65, 92-94), and is the most used HRQoL measure in 
patients with SLE and is recommended in clinical trials (17, 95). In a previous study (96), the 
SF-36 was shown to be sensitive to changes in terms of worsening and improvement in 
patients with active SLE.  
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6.1.3 Fatigue 
To measure self-reported fatigue over the previous week in patients and controls, the 
Multidimensional Assessment of Fatigue (MAF) was used. The MAF contains 16 items 
symbolizing four dimensions of fatigue; severity, distress, degree of interference on daily 
activities and timing (when present and if any changes during the past week). In items 1 to 
14, the respondents estimated severity and distress as well as the impact of fatigue on 
different activities in daily life from 1 to 10. In items 15 and 16, the participants estimated the 
overall frequency of fatigue and any changes during the past week using multiple choice 
responses. Items 1 to 15 can be used to calculate a global fatigue index (GFI) ranging from 1 
to 50 where 1 represents no fatigue and 50 represents severe fatigue. 
MAF has previously been used in patients with a number of different conditions and in 
different languages (97). Within rheumatology, the MAF has been used in patients with 
rheumatoid arthritis (98, 99), systemic sclerosis (100) and SLE (101). A recent review by 
Belza et al. (97) investigating the psychometric properties of MAF, showed that it exhibited 
high validity and reliability as well as good internal consistency in patients with different 
chronic diseases, including rheumatic diseases. 
6.1.4 Anxiety and depression 
The Hospital Anxiety and Depression Scale (HADS) (102) was used to measure anxiety and 
depression during the previous week in patients and controls. The measurement consists of 
seven questions concerning anxiety and seven questions concerning depression. Each 
question has four response options. The answers are summarized in two scales, anxiety 
(HADS-A) and depression (HADS-D) total index, which range from 0 to 21 where 0 
represents no symptoms and 21 represents maximum distress. A score from 8 to 10 is defined 
as mild to moderate inconvenience, and a score above 10 justifies deeper diagnostics and 
possible treatment for both the anxiety and the depression total index. 
The HADS has been tested in different contexts and in different populations; somatic, 
psychiatric and primary care patients, as well as in the general population (103). Strong 
validity and reliability have also been found in a Swedish population sample (104) as well as 
in a rheumatology setting (HADS-A) (105). 
For an overview of the self-assessment questionnaires used in the studies, see Table 2. 
6.2 DISEASE ACTIVITY AND DAMAGE 
6.2.1 Disease activity 
Disease activity was captured using the Systemic Lupus Activity Measure (SLAM) and 
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (95, 106) which are 
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physician-rated indices frequently used in research settings. Both SLAM and SLEDAI have 
been shown to be valid, reproducible and correlate well with other disease activity indices. 
SLAM measures signs and symptoms of the disease that have been present during the 
preceding month. Its score ranges from 0 to 84, and a score of seven or more is considered 
clinically important. SLEDAI measures medical signs from the disease during the previous 
10 days. Its score ranges from 0 to 105. Score 0 indicates no disease activity, 1 to 5 indicate 
mild activity, 6 to 10 indicate moderate activity, 11-19 indicate high activity and ≥20 very 
high disease activity. 
Both the physician and the patients scored global disease activity on VAS included in the 
SLAM, and the SLAM was also used to identify the most common location of pain in Study I 
(95). 
6.2.2 Disease damage 
Disease damage was captured using the physician-rated Systemic Lupus International 
Collaborating Clinics, American College of Rheumatology SLICC/ACR damage index (95). 
This index includes 41 items which cover 12 organ systems. Manifestations persisting 
continuously over six months after onset of SLE were recorded as damage, regardless of 
disease activity. SLE-specific co-morbidities as well as morbidity due to treatment for SLE 
are also included in the index. Score range 0 to 47. 
The indices for disease activity and damage were captured by an experienced rheumatologist. 
As a supplement to measuring disease activity, the Erythrocyte Sedimentation Rate (ESR) 
according to the Westergren method was used (107). The ESR is also included in the SLAM. 
In Study III, disease activity was measured by SLAM without lymphocytes and SLEDAI 
without complements and antibodies to double-stranded DNA (ds-DNA). 
6.3 INTERVIEWS 
The interviews were conducted individually by the same interviewer (EWa) using an 
interview guide based on questions which emerged when the authors analysed data from the 
self-reported questionnaires. The interview guide consisted of seven main questions, mostly 
open-ended (Table 4). For clarification and a deeper understanding, these questions were 
followed by supplementary questions, if needed. The interviews were concluded with the 
question do you want to tell us something more about your pain? 
A minor revision of the interview guide was made after a pilot interview with one of the 
controls who experienced pain.  
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The interviews were recorded using a mobile phone and the average time for the interviews 
was 40 minutes. The recordings were then transcribed verbatim and all words and utterances 
were printed. 
The participants were asked to choose what time and location they preferred for the 
interview. A secluded room in a care facility was offered, but the informants could also 
choose another location. Before any interview, a letter containing confirmation of the time 
and location was sent to the prospective informants. The letter also contained information that 
the interview would be recorded, that answering the questions was voluntary, and that the 
participant could discontinue the interview at any time. 
Table 4. Main questions in the interview guide 
How do you experience your pain? 
Has the pain affected your relationships? 
How does your pain affect your feelings of being ill? 
How do you deal with pain? 
Do you use any painkillers? 
What support do you need from healthcare providers to better deal with pain? 
Has the pain given you experiences that could mean something positive for you?  
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7 DATA ANALYSIS 
7.1.1 Statistics 
In Studies I-III, the data were analysed using descriptive statistics. Due to a non-normal 
distribution of collected data, different group size and ordinal data, non-parametric statistics 
were used. The results were presented as the median and interquartile range (IQR). For 
comparative statistics between groups, Chi-squared/Fischer’s exact test, the Sign Test, and 
the Mann-Whitney U Test were used. To compare paired data, Wilcoxon matched pairs test 
was used. Spearman’s Rank Correlation Coefficient (r) was used for correlation analysis. 
In Study III, the variation in self-reported pain was illustrated by calculating the difference 
between inclusion and the seven-year follow-up (inclusion minus follow-up). The difference 
represents an improvement if the difference consists of a positive number, except for SF-36 
where higher values indicate better health. 
A p-value less than 0.05 was considered statistically significant. 
Power analysis was calculated post hoc in Study II, between the whole patient group and the 
controls, between the low-pain group and the high-pain group, and between the controls and 
the low- and high-pain groups, respectively (Table 5). 
Non-parametric power was performed using the software nQuery Advisor 4.0 (Statistical 
Solutions, USA) and corresponding parametric power by STATISTICA 10 (Stat Soft 
Scandinavia AB, Uppsala, Sweden). Other statistical analyses were performed in 
STATISTICA 10 (Studies I and II) and 12 (Study III). 
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7.1.2 Division into groups based on pain 
When the intensity score for SLE-related pain the previous week on VAS (n=84) was 
analysed at inclusion (Study I), the median was 10.5 mm and the interquartile range (IQR) 
was 1 to 35.5 mm. Values above 40 mm constituted the scores beyond Q3 (>Q3) (Figure 2a). 
When dichotomized with the cut-off value of 40 mm, two groups appeared which did not 
overlap (Figure 2b). Thus, the cut-of value 40 mm, was chosen to divide the patients into two 
groups for comparative analyses. This cut-off value also coincides with the value often used 
to denote the threshold for moderate pain (84). The group scoring SLE-related pain 0-39 mm 
consisted of 64 patients and was named the low-pain group, and the group scoring 40-100 
mm consisted of 20 patients and was named the high-pain group.
Table 5. Power calculation 
 Patients 
versus 
controls 
Low-pain 
group versus 
controls 
High-pain 
group versus 
controls 
Low-pain 
group versus 
high-pain 
group 
Sample size 
(n) 
74 91 56 91 18 91 56 18 
Power 0.63 0.72 0.08 0.10 0.99 0.99 0.99 0.99 
Number of 
observations 
(in each group) 
to achieve a 
minimum 
power of 0.80 
111 1362 7 6 
Number of 
observations 
(in each group) 
to achieve a 
minimum 
power of 0.90 
148 1823 10 8 
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Figure 2a. Distribution of self-reported SLE-related pain 
 
Figure 2b. Distribution of self-reported SLE-related pain on VAS 
in the low-pain group and in the high-pain group 
This division into two groups was also used in Study II and maintained in the seven-year 
follow-up (Study III) where possible variations of SLE-related pain after seven years were 
investigated in each group. 
7.1.3 Content analysis 
In Study IV, the text from the verbatim transcribed interviews was analysed using content 
analysis and a classification scheme. Qualitative content analysis is a common research 
method for analysing data in terms of text in a structured manner based on its content or 
contextual meaning (108). The objective of qualitative research is not generalizability but 
transformability of the results from one context to another (109). To describe and understand 
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a subject, in the present study how the participants experience and manage SLE-related pain, 
a conventional approach was used. In the conventional content analysis, the codes and 
categories relevant for the purpose of the study emerge from the text data instead of 
predefined categories (108). The content of the text will thus be explored in an inductive way 
in which both the manifest and the latent content of the text may emerge (109-111).  
7.1.3.1 Analysis process 
The first step in the process was to read the entire text to acquire a sense of the whole (108, 
111). In the second step, the text was inserted into the first column of the classification 
scheme, labelled text. Text deemed meaningful to answer the research questions was marked. 
In the second column, labelled condensing, marked text from the first column was printed out 
verbatim. In the third column, labelled code, the condensed text from the second column was 
given a label consisting of one or a couple of words that are close to the text (108). 
Thereafter, the codes were transferred and numbered into a coding scheme, and codes with 
something in common were divided into categories and sub-categories. The categories and 
sub-categories were constructed to differ from each other in a distinct way so that a code 
could only fit one category or sub-category. The analysis process was not static in one 
direction but moved back and forth between the whole transcribed text and the columns in the 
classification scheme, and were discussed by the authors until consensus was reached. For an 
example of the analysis process, see Figure 3. 
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Figure 3. Example from the analysis process from codes to domain 
category 
domain 
co
de
s 
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8 ETHICAL CONSIDERATIONS 
The studies were approved by the Stockholm Regional Ethical Review Board. All 
participants who were asked to participate in the studies, the inclusion, the 7-year follow-up 
and the interview study, received verbal information about the studies and procedures. It was 
stressed that participation was voluntary, and that the participant could discontinue the study 
at any time without giving any reason. Those who were interested in participating after 
receiving verbal information were provided with written information about the study, the 
name of the persons responsible for the study, and a telephone number for the Study Nurses 
in the event of questions or other issues. The participants were given the opportunity to read 
through the information in peace and quiet, generally in their home but in some cases at the 
hospital.  
All participants provided written informed consent. The questionnaires were completed at the 
clinic to facilitate clarifying questions from the study participants during the procedure. This 
ensured there was little missing data. There was also time for questions and advice on health 
and the disease during the meetings with the nurses and the physicians. For any medical 
issues that emerged during the study visit, the controls were referred to appropriate healthcare 
providers. Feedback was also given on the results of the investigations. In the patient group, 
medical issues were managed at the clinic in agreement with the patient’s regular treating 
physician and nurse. All participants were encouraged to contact the Study Nurses if they had 
any questions regarding participation and procedures in the study, even after completion.  
The professionals in the study were aware of potential feelings of being forced to participate 
due to misguided loyalty or fear of negative consequences for their future care. Another 
identified negative risk was that the questions in the questionnaires could be considered as 
personally intrusive. To minimize this risk, the professionals emphasized continuously 
throughout the studies that participation was voluntary and that non-participation would not 
impact on future care and treatment.
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9 RESULTS 
9.1 STUDY I: PATIENT-REPORTED SLE-RELATED PAIN AND 
CHARACTERISTICS OF THE PATIENT POPULATION 
The patients in the high-pain group reported significantly higher pain scores on VAS, median 
(IQR) 70 (62 to 79) compared to the patients in the low-pain group, 6.5 (1 to 17.5) (p<0.001) 
and accounted for 24% of the study population. 
Disease duration (years) for the whole patient cohort was median (IQR) 9 (5 to 16) (Table 3). 
The high-pain group differed significantly from the low-pain group regarding shorter disease 
duration, higher disease activity measured by SLAM, SLEDAI and ESR, as well as higher 
global disease activity on VAS within SLAM (Table 6). 
 
There were no significant differences between the high-pain group and the low-pain group 
regarding the proportion of females and males, age, treatment with glucocorticoids and 
disease damage measured by SLICC (data not shown).  
SLAM indicated clinically important disease activity only in the high-pain group whereas 
SLEDAI indicated mild disease activity in both the low- and the high-pain group. The 
Spearman’s Rank Correlation Coefficient (r) between SLE-related pain and SLAM and 
SLEDAI, which included the whole patient cohort (n=84) was 0.44 and 0.35, respectively. 
Table 6. Significant differences between the low-pain group and the high-pain group  
 Low-pain group, 
n=64 
High-pain group, 
n=20 
pa 
Disease duration, yrsb 10(5 to 17.5) 5.5(3 to 9.5) 0.008 
Disease activity (SLAM)b 5.5(4 to 8) 10.5(8 to 14) <0.001 
Disease activity (SLEDAI)b 2(0 to 4) 4.5(2.5 to 9.5) 0.014 
ESR, mm/hb 17(12 to 26) 27(13.5 to 43) 0.044 
Disease activity measured by 
physicians (VAS mm/SLAM)b, 
n=27 
7(3 to 11) 25.5(13 to 30) 0.029 
Disease activity measured by 
patients (VAS mm/SLAM)b, 
n=81 
13(8 to 23) 52.5(41 to 68.5) <0.001 
aMann-Whitney U Test, bmedian with interquartile range (IQR), p value denotes statistical 
differences between the low-pain group and the high-pain group 
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The physicians scored significantly lower global disease activity on VAS in SLAM, median 
(IQR) 12 (4 to 23) compared to the whole patient cohort 19 (10 to 50) (p=0.007). 
9.1.1 Patient-reported pain characteristics and locations 
Compared to the low-pain group, the high-pain group scored significantly higher pain 
intensity in the total, sensory, and in the affective pain intensity index of SF-MPQ. Moreover, 
the high-pain group indicated pain for more descriptive words (Table 7). 
 
The descriptive words most reported in the high-pain group as moderate were stabbing 
(n=6/30%), burning (n=9/45%) and aching (n=10/50%) and as severe heavy (n=5/25%), 
exhausting (n=5/25%) and tender (n=8/40%). In general, a larger proportion of the high-pain 
group, compared to the low-pain group, reported moderate and severe pain for each word in 
the SF-MPQ (Figure 4).  
Table 7. Pain characteristics according to the short-form McGill Pain Questionnaire (SF-
MPQ) in the low- and high-pain group 
 Low-pain group, 
n=84 
High-pain group, 
n=20 
pa 
SF-MPQ total intensity score for 
descriptive wordsb 
2(0 to 5) 14.5(5.5 to 20.5) <0.001 
The SF-MPQ sensory indexb 2(0 to 4) 13(7 to 17) <0.001 
The SF-MPQ affective indexb 0(0 to 4) 8.5(4 to 10.5) 0.002 
Descriptive wordsb 2(0 to 4) 8.5(4 to 10.5) <0.001 
a Mann-Whitney U Test, bmedian with interquartile range (IQR), p value denotes statistical 
differences between the low-pain group and the high-pain group 
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Figure 4. Descriptive words expressed as a percentage to signify moderate and severe pain in 
the low-pain group and the high-pain group 
Most patients in the high-pain group (70%) denoted their present pain as distressing, and 
conversely, the low-pain group (55%) denoted no pain in the present pain index (PPI). There 
was a positive correlation between self-reported SLE-related pain on VAS and the number of 
descriptive words used; Spearman’s Rank Correlation Coefficient (r) 0.78 when the whole 
patient cohort was included. 
The most common pain location for the low- and high-pain group was the joints, even though 
only a minority exhibited objectively verified arthritis. Other locations for pain according to 
SLAM were the head, muscles and abdomen (Figure 5).
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Figure 5. Distribution of pain location according to SLAM in the low- and high-pain groups 
When looking at the whole patient cohort, patients with arthritis verified by the physician, 
had significantly shorter disease duration, median (IQR) 3 (1 to 11) years compared to those 
with no confirmed arthritis 9 (5 to 17.5) (p=0.027) years. 
9.2 STUDY II: SELF-REPORTED OVERALL PAIN, HEALTH-RELATED 
QUALITY OF LIFE, FATIGUE, ANXIETY AND DEPRESSION 
In Study II, the low- and the high-pain groups were compared to age- and gender-matched 
controls from the general population for pain, HRQoL, fatigue, anxiety and depression. 
9.2.1 Self-reported overall pain 
Overall pain on VAS was used for appropriate comparison between the patient cohort and the 
controls. In the patient cohort, overall pain exhibited the same pattern as for SLE-related pain 
with a significant difference between the low-pain group, median (IQR) 11 (2 to 22) and the 
high-pain group, 72 (64 to 80) (p=<0.001). No significant difference was found between self-
reported SLE-related pain and overall pain in the low-pain group or the high-pain group 
(p=0.15 and 0.06 respectively). The overall pain score for the controls, median (IQR) 5 (0 to 
36), did not differ significantly from the low-pain group (p=0.65) but differed significantly 
from the high-pain group (p<0.001). 
9.2.2 Self-reported health-related quality of life 
The high-pain group reported a significantly lower score, meaning poorer HRQoL, in all 
dimensions of SF-36 compared to the low-pain group and the controls (p<0.001 to 0.005 and 
p<0.001, respectively) (Figure 6).
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Figure 6. Scores as median by the controls, the low- and high-pain groups in all domains in SF-36 
The low-pain group reported similar scores to the controls in half of the dimensions of SF-36. 
However, the scores by the low-pain group were significantly lower in the dimensions 
physical function (p<0.001), general health (p<0.001), vitality (p=0.02) and social function 
(p=0.02) compared to the controls. 
Low-to-moderate correlations were found between scores in the dimensions of SF-36 
(excluding bodily pain) and scores for overall pain in the patients; Spearman’s Rank 
Correlation Coefficient (r) ranged from -0.29 to -0.54, and in the controls from -0.30 to -0.56. 
Further, the correlations between scores in the dimensions of SF-36 (excluding bodily pain) 
and SLE-related pain ranged from -0.43 to -0.58. The correlations between scores in the 
dimensions of SF-36 (including bodily pain) and SLAM ranged from -0.26 to -0.57 and 
SLEDAI from -0.17 to -0.38. 
9.2.3 Self-reported fatigue 
In the high-pain group, 50% of the patients scored fatigue every day compared with 33% in 
the low-pain group and 24% in the controls. 
Fatigue, measured by the summary general fatigue index (GFI) in MAF, was significantly 
higher in the high-pain group, median (IQR) 36.5 (32.5 to 39.7), compared to the low-pain 
group, 23 (14.6 to 34.1) (p<0.001), and the controls 19.4 (11.6 to 29.1) (p<0.001). No 
significant difference was found between the low-pain group and the controls (p=0.09). 
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The Spearman’s Rank Correlation Coefficient (r) between MAF/GFI and SLE-related pain, 
and MAF/GFI and overall pain in the patient cohort was 0.53 and 0.49, respectively, and in 
the controls the correlation between MAF/GFI and overall pain was 0.40. 
The correlation (r) between MAF/GFI and the disease activity indices SLAM and SLEDAI 
was 0.48 and 0.29, respectively. 
9.2.4 Self-reported anxiety and depression 
The total anxiety index in HADS indicated symptoms of mild-to-moderate inconvenience for 
the patients in the high-pain group, median (IQR) 9 (6.5 to 11.5), whereas for the patients in 
the low-pain group and the controls, the total anxiety index indicated no symptoms of 
anxiety, median (IQR) 4 (3 to 8) and 4 (2 to 7), respectively. 
The total depression index indicated no symptoms of depression in the high-pain group, 
median (IQR) 7.5 (5.5 to 9), in the low-pain group 3 (1 to 5) nor in the controls 2 (1 to 4). 
However, the high-pain group scored a significantly higher total index for anxiety and 
depression compared to the low-pain group (p<0.001) and the controls (p<0.001). No 
significant difference was found between the low-pain group and the controls regarding the 
total anxiety and depression index (p=0.81 and p=0.19, respectively). 
The Spearman’s Rank Correlation Coefficient (r) between SLE-related pain and the total 
anxiety index in the whole patient cohort was 0.43, and 0.52 between SLE-related pain and 
the total depression index. 
9.3 STUDY III: SEVEN-YEAR FOLLOW-UP OF SELF-REPORTED PAIN, 
HRQOL, FATIGUE, ANXIETY AND DEPRESSION 
9.3.1 Self-reported pain 
When investigating the whole patient cohort (n=64) at the seven-year follow-up, there was no 
significant difference between inclusion, in this study named year 0, and the seven-year 
follow-up, named year 7, concerning intensity of self-reported overall pain and SLE-related 
pain during the previous week using VAS (Table 8a). When the patients were divided into 
groups by pain intensity which was scored at year 0, the patients in the high-pain group 
scored a lower level of overall pain and significantly lower SLE-related pain at year 7 
compared to year 0 (Table 8a). However, the patients in the low-pain group (n=50) reported 
similar scores of overall pain and SLE-related pain at year 7 as they did at year 0 (Table 8a). 
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Table 8a. Overall pain and SLE-related pain at inclusion and seven-year follow-up in patients divided into groups by pain, and controls 
 The whole patient cohort, 
n=64 
pa Low-pain group, n=50 pa High-pain group, n=14 pa Controls, n=68 pa 
 Year 0 Year 7  Year 0 Year 7  Year 0 Year 7  Year 0 Year 7  
Overall pain, 
VAS, mmb 
17 
(3 to 45) 
23 
(6 to 45) 
0.98 13 
(3 to 23) 
18 
(4 to 35) 
0.21 70 
(49 to 79) 
49 
(14 to 70) 
0.050 5 
(0 to 29) 
11 
(2 to 30) 
0.09 
Changec in overall 
pain, VAS, mmb 
na 0 
(-12 to 15) 
na na -1 
(-12 to 6) 
na na 33 
(-4 to 51) 
na na -2 
(-13 to 14) 
na 
SLE-related pain, 
VAS, mmb 
11 
(2 to 31) 
11 
(1 to 33) 
0.92 7 
(1 to 16) 
8 
(1 to 22) 
0.19 69 
(50 to 72) 
43 
(15 to 66) 
0.035 na na na 
Changec in SLE-
related pain, 
VAS, mmb 
na 1 
(-7 to 7) 
na na 0 
(-6 to 2) 
na na 32 
(-13 to 48) 
na na na na 
Chronic widespread 
pain/ACR90(42)d 
na 20 
(31%) 
na na 13 
(26%) 
na na 7 
(50%) 
na na 9 
(13%) 
na 
aWilcoxon matched pairs test, bmedian with interquartile range (IQR), cchange between year 0 and year 7, dnumbers (%), na=not applicable, p value denotes statistical 
differences between inclusion (year 0) and seven-year follow-up (year 7) 
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The change in SLE-related pain between year 0 and 7 was larger in the high-pain group 
median (IQR) 32 (-13 to 48) whereas it was 0 (-6 to 2) in the low-pain group. 
Further analysis of self-reported SLE-related pain in the high-pain group at year 7 showed 
that half of the patients in this group (n=7) reported significantly lower level of SLE-related 
pain at year 7, and the other half of the high-pain group (n=7) reported an unchanged level of 
Table 8b. Self-reported pain, use of analgesics and disease activity in the patients with decreased and 
remaining pain at inclusion and seven-year follow-up 
 Patients with decreased pain, 
n=7 
pa Patients with remaining pain, 
n=7 
pa 
 Year 0 Year 7  Year 0 Year 7  
Overall pain, VAS, 
mmb 
67(51 to 71) 14(10 to 44) 0.031 78(46 to 96) 64(52 to 75) 0.92 
Changec in overall 
pain, VAS, mmb 
na 48(31 to 61) na na -0.5(-18 to 35) na 
SLE-related pain, 
VAS, mmb 
70(60 to 72) 15(2 to 37) 0.021 67(47 to 83) 66(55 to 73) 0.87 
Changec in SLE-
related pain, VAS, 
mmb 
na 45(35 to 65) na na -13(-20 to 28) na 
Problems SLE-
related pain, VAS, 
mmb 
na 15(3 to 29) na na 54(47 to 88) na 
Pain>3 monthsd na 4(57) na na 7(100) na 
Chronic widespread 
pain/ACR90(42)d 
na 0(0) na na 7(100) na 
Numbers of body 
regions with pain>3 
monthsb 
na 4(3 to 4) na na 11(9 to 15) na 
Use of analgesics 
regulard 
na 1(14) na na 6(86) na 
Use of analgesics as 
neededd 
na 4(57) na na 1(14) na 
SLAMb,e 12(7 to 19) 5(3 to 6) 0.018 9(5 to 14) 8(6 to 11) 0.40 
Patients’ reported 
global disease 
activity, VAS/SLAM, 
mmb 
62(49 to 70) 6(3 to 34) 0.043 50(44 to 81) 50(49 to 73) 0.69 
Physicians’ reported 
global disease 
activity, VAS/SLAM, 
mmb 
na 5(2 to 10) na na 15(9 to 17) na 
Difference between 
patients’ and 
physicians’ global 
disease activity, 
VAS/SLAM, mmb 
na 4(1 to 24) na na 35(33 to 46) na 
SLEDAIb,f 7(3 to 16) 0(0 to 2) 0.046 2(0 to 4) 0(0 to 2) 0.36 
SLICCb 1(0 to 4) 2(1 to 4) 0.11 0(0 to 2) 1(0 to 3) 0.043 
a Wilcoxon matched pairs test, bmedian with interquartile range (IQR), cchange between year 0 and year 7, 
dnumbers(%), ewithout lymphocytes, fwithout complement and ds-DNA, p value denotes differences 
between inclusion and seven-year follow-up 
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SLE-related pain at year 7 compared to year 0 (Table 8b). Therefore, the high-pain group was 
further divided into two groups, patients with decreased pain and the patients with remaining 
pain, as illustrated in Figure 7. 
 
All the patients with remaining pain reported pain lasting more than three months; the pain 
drawing indicated chronic widespread pain according to the definition by Wolf (42). 
Comparison of pain and characteristics between the patients with decreased and remaining 
pain are presented in Table 8b. 
No significant difference was found for overall pain between the controls and the low-pain 
group and those with decreased pain at year 7. However, when the controls were compared to 
the whole patient cohort (n=64) and to the patients with remaining pain, the controls reported 
significantly lower overall pain at year 7 (p=0.032 and p=<0.001, respectively). 
The score for the total pain intensity index of SF-MPQ and numbers of descriptive words 
used remained the same at year 7 as at year 0 for patients in the low-pain group and patients 
with remaining pain. However, patients with decreased pain reported a significantly lower 
total index at year 7, median (IQR) 2 (1 to 4) compared to 17 (5 to 22) at year 0 (p=0.028) 
and fewer descriptive words, 2 (1 to 3) at year 7, compared to 9 (7 to 11) at year 0. 
 
Figure 7. Division into groups by SLE-related pain intensity at inclusion and seven-year 
follow-up 
 
 
n=6 
Remaining pain, 
n=7 
Seven-year follow-up, n=64 Lost to follow-up Inclusion, n=84 
High-pain group, 
n=20 
Low-pain group, 
n=64 
n=14 
Decreased pain, 
n=7 
Low-pain group, 
n=50 
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9.3.2 Characteristics and medications 
No significant difference in age or disease duration was found between the patient groups 
divided by pain; the low-pain group, the patients with decreased pain and remaining pain 
(data not shown). 
All patients in the cohort had decreased medication in terms of DMARD and glucocorticoids 
at year 7. The largest dose reduction of glucocorticoids was found among the patients with 
decreased pain (milligram), median (IQR) 5 (0 to 12.5). All, except one, of the patients with 
remaining pain used analgesics regularly, n=6 (86%) compared to 12 (24%) of the patients in 
the low-pain-group and 1 (14%) of the patients with decreased pain. 
9.3.3 Disease activity and damage 
Disease activity according to the SLAM index was statistically unchanged between year 0 
and year 7 for the patients with remaining pain, and significantly higher compared to the 
patients in the low-pain group and those with decreased pain (p=0.006 and p=0.017 
respectively). Disease activity had decreased significantly according to the SLAM for the 
patients with decreased pain (Table 8b) and for the patients in the low-pain group at year 7, 
median (IQR) 4 (2 to 7) compared to year 0, 5 (4 to 8) (p=0.007). Conversely, there was no 
statistical difference between the patients in the different pain subgroups in regard to disease 
activity measured by the SLEDAI at year 7 (data not shown). The SLEDAI decreased 
significantly only in patients with decreased pain at year 7 (Table 8b). When comparing 
SLEDAI at year 0 for patients with decreased and remaining pain, the SLEDAI was higher in 
the patients with decreased pain at year 0, even though the difference was not statistically 
significant (p=0.073). Yet, there was no significant difference in the SLEDAI measured at 
year 0 for patients in the low-pain group and patients with remaining pain. 
Global disease activity reported by the physicians on VAS in SLAM at year 7 was 
significantly lower compared to that reported by patients in the low-pain group, median 
(IQR) 5 (0 to 12), patients with decreased pain and patients with remaining pain (Table 8b) 
(p<0.001, p=0.043 and p=0.028 respectively). The largest difference was found between the 
physicians and patients with remaining pain (Table 8b). 
Despite a higher damage index using SLICC in patients with decreased pain (Table 8b) at 
year 7, this was not significantly different from patients with low pain and patients with 
decreased pain. 
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9.3.4 Health-related quality of life 
Except for a worsening of the dimension vitality of the SF-36, median change (IQR) -20 (-35 
to -15) at year 7, there was no other significant difference in the dimensions of the SF-36 
between year 0 and year 7 for patients with remaining pain (Figure 8a). Patients in the low-
pain group scored similar levels at year 7 as at year 0 in all dimensions of the SF-36 except 
for a reduction in the dimensions physical function, median change (IQR) 0 (-10 to -5), and 
bodily pain, 0 (-21 to 1) (Figure 8b). Conversely, patients with decreased pain scored 
improvement in all dimensions of the SF-36 (Figure 8c). 
 
  
  
Figures 8 a-d. Health-related quality of life (SF-36) (range 0-100), presented as median, for 
patients with SLE, grouped by SLE-related pain and controls at year 0 and year 7. a patients 
with remaining pain, b patients in the low-pain group, c patients with decreased pain, d 
controls 
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Except for the dimension mental health of the SF-36, patients with remaining pain scored a 
lower HRQoL at year 7 in all dimensions of the SF-36 than patients in the low-pain group, 
patients with decreased pain and the controls (p=<0.001 to 0.012). However, there was no 
difference at year 7 in any dimension of the SF-36 between patients in the low-pain group 
and patients with decreased pain.  
No significant difference was found between year 0 and year 7 in any of the dimensions of 
the SF-36 for the controls (Figure 8d). Nor was there any difference between controls and 
patients with decreased pain in any dimension of the SF-36. However, the controls scored 
significantly better for HRQoL compared to patients in the low-pain group in the dimensions 
physical function (p=0.016), general health (p= 0.007), social function (p=0.023) and scored 
close to significant in bodily pain (p=0.053). 
9.3.5 Self-reported fatigue 
The score for GFI/MAF was unchanged between year 0 and year 7 in patients with remaining 
pain (Figure 9) and these patients also scored significantly higher GFI at year 7 than patients 
in the low-pain group (p=0.017), patients with decreased pain (p=0.017) and the controls 
(p=0.001). In contrast, patients with decreased pain scored significantly lower GFI at year 7 
compared to year 0, whereas patients in the low-pain group and the controls scored similar 
levels of GFI at year 0 and year 7 (Figure 9). No significant difference in GFI at year 7 was 
detected between the patients in the low-pain group, the patients with decreased pain, or the 
controls.
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9.3.6 Self-reported anxiety and depression 
No symptoms of anxiety or depression were found in the total indices of HADS at year 7 in 
any patient in the pain subgroups nor in the controls. Patients with decreased pain scored a 
significantly lower total index for both anxiety and depression. Moreover, there was no 
significant difference in scores for the anxiety total index at year 7 between the patient 
groups: low-pain group, patients with decreased pain, and patients with remaining pain, nor 
for the controls (Figure 10a). However, patients with remaining pain scored a significantly 
higher total index for depression than patients in the low-pain group, patients with decreased 
pain and the controls (Figure 10b). 
Figure 9. General fatigue index (GFI/MAF) (range 1-50) for patients with SLE 
as grouped by SLE-related pain and controls at year 0 and year 7, 
a Wilcoxon Matched Pairs Test 
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9.4 STUDY IV: INTERVIEWS WITH PATIENTS WITH SLE-RELATED PAIN 
The transcribed text from 20 interviews produced 296 codes which created 39 categories and 
34 subcategories. Saturation, the point at which no new codes were obtained, was reached 
after the 15th interview. The categories and subcategories were further divided into seven 
domains which were defined by the questions in the interview guide and by the narratives 
from the informants (Figure 11). 
 
 
 
Figures 10 a+b. HADS, total index for anxiety and depression (range 1-21) for patients with 
SLE as grouped by SLE-related pain and controls at year 0 and year 7, a total index for 
anxiety, b total index for depression, a Wilcoxon Matched Pairs Test 
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Figure 11. The seven domains that emerged from the interviews 
9.4.1 Duration and sensation 
The pain was portrayed by the informants as long-standing and always present, as well as 
migrating between different body areas including throughout the whole body. The pain 
intensity and duration in different body areas could vary over time and during the day. 
Typically, the informants related that the nature of the pain was unpredictable, hard to 
describe and similar to the pain with flu or after tough exercise. Mainly, the pain was located 
in the musculoskeletal system, but the informants also commented on headache, pain in the 
abdomen and the lungs, pain from wounds, blisters and rashes as well as pain related to 
Raynaud´s phenomenon. The intensity of the pain could be intrusive and require all their 
concentration; sometimes, however, it was possible to be distracted. 
Several factors could trigger or exacerbate the pain such as stress or other emotions. Other 
common triggers were physical activity and environmental factors such as cold and changing 
weather. Getting relief from pain after making extensive lifestyle changes was also described: 
 
9.4.2 Pain and fatigue 
Pain and fatigue were closely linked and reinforced each other. Almost always, pain was 
followed by a loss of energy and physical weakness, causing physical as well as mental 
“…. I made a sound …. a sensible decision and closed down my business and 
took a job … so it’s probably the fact that life is less hectic that’s made the pain 
disappear (#5) 
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fatigue which reduced the ability to carry out daily activities. Because of this interdependent 
relationship between pain and fatigue, the informants’ ability to deal with pain was dependent 
on the degree of fatigue. 
9.4.3 Emotional and existential dimensions 
Several emotions were connected to pain including anger, despair, sadness, fear, hopelessness 
and self-pity. Frustration and irritation were expressed at the pain-associated limitations in 
daily life. The informants reflected on how their life with a chronic disease, such as SLE and 
pain, had turned out and asked themselves: why me? They also identified future dreams and 
plans which could not be realised because of the pain and their future sometimes felt 
uncertain: 
 
However, the informants felt, at least in part, that SLE and related pain was something that 
was now incorporated into their lives and considered illness like a cold or flu and something 
affecting them over and above their everyday life with SLE. 
9.4.4 Thoughts about pain 
The informants’ thoughts about pain included the cause of pain and hope of improvement. 
They associated their pain to flares of an inflammatory condition (SLE) and they considered 
themselves able to distinguish SLE-related pain from other sources of pain. Thus, they might 
still be uncertain about the actual cause of the pain. The hope of improvement included the 
ability to endure pain. 
9.4.5 The ways in which pain intrudes into daily life 
The impact of pain in daily life could be divided into five dimensions (Figure 12).
“… I wasn’t able to work, I can’t, I can’t stand up for very long, so all my dreams 
have come to nothing …” (#6)  
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Limitations of the physical ability included difficulties with mobility, reduced strength and 
impaired balance. Personal care was also highlighted by the informants such as difficulties 
with dressing, putting on and off shoes and taking medicine out of a box. Difficulties with 
different household chores included cooking, cleaning and heavy lifting. Difficulties with 
planning were mainly related to the unpredictable course of the pain. The pain could impact 
the informants’ ability to carry out different roles in relation to others such as family, 
partner, children, friends and co-workers. The pain-related limitations created dependence on 
others which in turn created guilt and the feeling of being a burden to others: 
 
However, family members were considered to give valuable help and support. 
9.4.6 Dealing with pain 
The informants used several strategies to reduce pain and its impact on daily life. The 
strategies could be divided into two main areas which could be used alternatively and/or 
simultaneously: 
Inner resources included; acceptance, acquired knowledge/experience, adaption, conscious 
choices, inherent characteristics, repression and willpower: 
 
Practical actions included; aids/devices, cures/practical interventions, medication, and 
physical activity. 
Figure 12. Five dimensions in daily life affected by pain 
“… if I hadn’t been in this situation, my relationships and finances might have 
been completely different…” (#8) 
“… I don’t think they notice so much at work, because you try … I really try to 
keep it together” (#15) 
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These strategies resulted in varying degrees of pain alleviation and benefit, but rarely 
complete pain relief. The informants could also be unsure as to whether the strategies were 
efficient. 
Despite the negative impact of pain, the informants found that pain could at least in some way 
contribute to self-development, such as inner strength, and to appreciating other aspects of 
their life. They also thought that their experience of pain increased their ability to understand 
the difficulties of others. 
9.4.7 Support from healthcare providers 
The invisibility of pain was identified by the informants as a reason for communication 
barriers between the patients and healthcare providers. Lack of confirmation of the pain by 
healthcare providers created feelings of being neglected, not being taken seriously or not 
being seen as credible. Conversely, being treated well and acknowledged by healthcare 
providers created security, confidence and gave hope. Therefore, the informants’ earlier 
experiences of meeting healthcare providers were the starting point when they expressed 
suggestions for interventions from healthcare providers that were intended to support the 
informants’ ability to deal with pain. The suggestions included the following topics: be 
treated well and acknowledged, good accessibility to different professions, not being a 
messenger in their own care, alternative ways of maintaining contact, individually-tailored 
advice and information, interventions and support irrespective of economic circumstances, 
rehabilitation in warm climate, development of care and better treatment including 
medication: 
 
“… then they look in the records and say … oh yes, you’ve had a problem with SLE … 
it might be the SLE … go and see the rheumatologist … and so I go to the 
rheumatologist … why have you come here with that problem, you should go to the 
healthcare centre … and so you’re bounced backwards and forwards and then you 
end up in emergency because someone thinks that’s best and then they say …what 
are you doing here … and it’s always us patients who get the blame if it isn’t right … 
so then you apologise and in the end no-one … you don’t go unless you really have 
to … and then you just get … why didn’t you come earlier?” (#8) 
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10 DISCUSSION  
10.1 SELF-REPORTED PAIN, HRQOL, FATIGUE, ANXIETY AND DEPRESSION 
Overall, the studies in this thesis showed that most patients with SLE reported low intensity 
of disease-related pain. Moreover, the pain tended to decrease in intensity over time and with 
the course of the disease. Despite these gratifying results, a substantial proportion of the 
current cohort (24%) reported high intensity of disease-related pain (VAS≥40 mm) at 
inclusion (year 0) and, for some of these patients, the pain remained from year 0 to year 7. 
Despite the fact that high pain intensity occurred in a minority of the present cohort, the 
results clearly demonstrate a high symptom burden with impaired HRQoL, more fatigue, and 
more symptoms of anxiety and depression in these patients. Therefore, the patients with high 
pain intensity are in need of special attention from healthcare providers. 
Earlier studies have reported poorer HRQoL in general among patients with SLE compared 
to the general population (17, 18, 66, 112). However, in this thesis, patients in the low-pain 
group did not differ from the controls in any significant way in regard to HRQoL except for 
worse scores in the dimensions physical function, general health and social function of the 
SF-36 at both year 0 and 7. Thus, the results concerning HRQoL emphasize the importance 
of identifying subgroups among patients with SLE to enable identification of important 
differences. Pain in SLE appears to be an important symptom which, if treated, will improve 
HRQoL because decreased pain has been shown to be associated with improved HRQoL 
(69), and freedom from pain is identified as a predictor for better HRQoL (67). Gallop et al 
(23) illustrated the great impact of subjective symptoms like pain on HRQoL in a conceptual 
model which emphasized the benefits for health if subjective symptoms are treated.  
As expected, in this thesis the score for fatigue was higher in patients with higher levels of 
pain thereby confirming previous studies that had suggested a close relationship between pain 
and fatigue (28, 30, 71). More surprisingly, the results revealed that the patients in the low-
pain group did not differ significantly from the controls in regard to fatigue. 
As there were no significant signs of anxiety or depression in any patients grouped by pain or 
in the controls at year 7 (113), anxiety and depression appear to be the symptoms least 
affected by pain in this cohort. Further, patients with remaining high pain intensity at year 7 
did not differ significantly from patients in the low-pain group, patients with decreased pain, 
and the controls in regard to the anxiety total index in HADS and the dimension mental 
health in SF-36. Thus, the results for mental health from study III tended to contradict a 
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previous study by Bachen et al (19) who found poorer mental health among women with SLE 
compared to the general population.  
Results from the interview study (Waldheim et al 2018, manuscript), in which all the 
informants had reported high intensity of SLE-related pain at least at some point, confirmed 
the results from the questionnaires and expanded the knowledge on the impact of pain in 
SLE. These deeper insights on the impact of pain on health and daily life were not possible to 
obtain with questionnaires alone. However, the questionnaires appeared to be valuable for 
screening health status and symptoms.  
The results from the interviews highlighted that SLErelated pain is one of the hardest-to-live-
with symptoms, as reported in a recent study by Morgan et al (114). Moreover, the results 
from study IV were mainly consistent with the results from a review by Sutanto et al (115) 
which included 46 qualitative studies and showed that the informants with SLE described 
disease-related pain as unpredictable, disabling and interfering with daily activities such as 
personal care, work and exercise. Further, similarly to the informants in study IV, the 
informants in the review by Sutanto el al (115) depicted that stress and the weather could 
exacerbate pain, and some related that there was a lack of understanding from their 
surroundings and healthcare providers for invisible symptoms such as pain.  
In summary, the repeated, similar results from studies in different countries, mainly in 
western countries, clearly demonstrate that pain is associated with a high symptom burden 
and subsequent negative impact on health and daily life. Targeted interventions from 
healthcare providers are therefore needed to support the patients in alleviating and dealing 
with pain. Further, the results from this and previous studies highlight the importance of 
measuring health status and subjective symptoms in clinical settings when exploring 
subjective outcomes of care and medical treatment.  
10.2 SELF-REPORTED PAIN AND DISEASE DURATION 
In study I, disease duration was significantly shorter in the high-pain group compared to the 
low-pain group. This result indicates that pain in SLE tends to be less common and have less 
intensity later in the course of the disease. This has also been reported in the study by 
Leuchten et al (47). Furthermore, It has been shown that the inflammatory activity decreases 
with time over the natural course of the disease (13); moreover, treatment duration increases, 
resulting in better control of the inflammation and associated symptoms. The patients may 
also acquire skills to manage pain. Accordingly, pain intensity decreased in the high-pain 
group at year 7, but only among the half of the patients. Therefore, the results from year 0 and 
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year 7 suggest the possibility of transition from pain induced by inflammation in the early 
course of SLE to pain induced by other mechanisms in the pain processing pathways (34, 43, 
45, 46). This hypothesis is supported by the reported higher prevalence of fibromyalgia 
syndrome in patients with SLE (17 to 40%) compared to the general population (3-5%) as 
well as proposals for common mechanisms in SLE and fibromyalgia syndrome (116). 
However, the results from this thesis did not provide answers as to the cause of the pain, and 
neither was this the aim of the studies. Further studies and larger cohorts are required to 
investigate different mechanisms behind prolonged pain in patients with SLE and other 
rheumatic diseases.  
10.3 SELF-REPORTED PAIN AND DISEASE ACTIVITY 
At year 0, there was a significant difference in disease activity between the patients in the 
low- and high-pain group, where both SLAM and SLEDAI were significantly higher in the 
high-pain group. This can be explained by inadequately controlled inflammatory activity in 
patients with shorter disease duration, such as in the high-pain group. However, in the 
patients with remaining pain, SLAM was unchanged after seven years and was significantly 
higher compared to patients in the low-pain group and patients with decreased pain. 
However, there was no significant difference in SLEDAI between the patients grouped by 
pain at year 7, which suggests that pain rather than inflammatory activity impact the SLAM. 
For example, fibromyalgia syndrome is known to interfere with ratings of disease activity and 
may leads to a higher disease activity index (117). Further, SLAM includes more subjective 
variables than SLEDAI (95), and thereby subjective symptoms like pain and fatigue have a 
larger impact on the SLAM index. 
The discrepancies in reported global disease activity on VAS/SLAM between the patients and 
the physicians, as well as disparity between SLAM and SLEDAI, indicate a risk of 
communication barriers. As shown before, patients with SLE report their disease activity 
based on more subjective experiences including the impact of the disease on life as a whole 
(118). In contrast, healthcare providers base their assessment on more commonly regarded 
objective measures such as laboratory findings and physical examinations (18, 119, 120). It is 
also known that a higher degree of pain correlates to greater discordance between patients 
and physicians (121). 
10.4 SELF-REPORTED PAIN AND UNMET NEEDS 
In the interview study (Waldheim et al 2018, manuscript), the informants expressed feelings 
of not being taken seriously when they talked about their pain with healthcare providers. The 
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informants thought this lack of acknowledgement was due to the invisible nature of pain. 
They also perceived that their pain was trivialized and that they were used as messengers in 
their own care. These dissatisfactions over unmet needs were also found in a review by 
Serrano-Aguilar et al (8), where pain was one of the most frequently reported health problems 
in patients with SLE. In that review, the patients thought the lack of attention to pain by 
healthcare providers was due to the non-life-threatening nature of the pain. The authors also 
found there was dissatisfaction with the poor coordination between different healthcare 
providers. Even though pain was not the focus in the study by Hale et al (122), the informants 
with SLE expressed dissatisfaction with not being listened to when relating their problems, as 
well as dissatisfaction with a lack of coordination between different healthcare providers. In a 
recent study by Golder et al (123), the authors suggest that the different priorities of concerns 
create a barrier in communication between patients and healthcare providers.  
10.5 INTERVENTIONS TO REDUCE PAIN 
In study IV, the informants used many strategies to deal with pain, both inner resources and 
practical actions as well as combinations of these. Despite these strategies, adaption to their 
situation and the extensive energy used, the informants did not achieve complete relief from 
pain. However, they could identify areas which they thought could be beneficial when 
dealing with pain, and which should be taken into account when developing and 
implementing new interventions aimed at alleviating pain.  
Based on previous studies, interventions for conditions with longstanding pain should be 
multidisciplinary (40, 51, 52). As confirmed in the study by Serrano-Aguilar et al (8), 
involving patients in the development of clinical guidelines in which their needs are 
addressed is one way to approach person-centred care and to implement individual targeted 
interventions. 
The informants in study IV commented on physical activity as beneficial to increase their 
wellbeing when pain is a major symptom. However, physical activity could also trigger pain 
and thus it was hard for the informants to reach the beneficial level of physical activity. In a 
previous study by Arvidsson et al (67), regular low intensity exercise promoted HRQoL in 
patients with a variety of rheumatic diseases. In contrast, a previous study by Boström et al 
(124) investigating high intensity exercise in patients with SLE, did not show any significant 
improvement in HRQoL. On the other hand, it was found that high intensity exercise did not 
negatively impact the disease in patients with mild to moderate SLE disease activity. 
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Another study by Arvidsson at al. (52), which looked at a problem-based learning (PBL) 
intervention, showed improved empowerment in patients with various rheumatic diseases and 
chronic musculoskeletal pain. Greco et al (51) found a positive effect of acupuncture in a 
randomized pilot study and Yuen et al (125) found beneficial effects on pain, fatigue, anxiety 
and depression using an interactive video system. 
Despite the fact that there are few intervention studies aimed to reduce pain and improve 
health in patients with SLE, some report positive results and thereby give hope for future 
research and development of individual targeted interventions. 
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11 METHODOLOGICAL CONSIDERATIONS 
The post hoc power analysis which was performed at year 0 (126) showed low power when 
comparing patients in the low-pain group to the controls. However, this low power 
strengthens the results in this thesis by revealing that patients in the low-pain group were so 
similar to the controls that a difference is hard to detect. The post hoc power analysis showed 
that a large cohort was needed to detect a difference between the low-pain group and the 
controls; this was not possible to include in the studies for this thesis. The relatively small 
cohort size and the cross-sectional design in studies I-III could limit generalization of the 
results. However, because most patients with SLE in Sweden should be affiliated with a 
rheumatologist (127-129), the cohort was considered to be representative for the disease. The 
low proportion of men to women did not allow comparison between genders, especially when 
divided into smaller groups for reported pain at year 7. Both the patients and the sex- and 
age-matched controls were recruited from the same greater urban area which made the 
comparisons between patients and controls reliable. 
For ethical reasons, no data were collected from patients who participated at year 0 but who 
declined to participate at year 7. This prevented comparison between those who participated 
and those who did not. Thus, it cannot be excluded that this thesis would have produced 
different results if data for those who declined to participate had been included. 
Notwithstanding, at year 7, age and disease duration were compared for those who 
participated and those who did not (from the original cohort), because this did not require 
collection of new data. As far as we know, few studies have investigated self-reported SLE-
related pain, HRQoL and other associated symptoms in the same cohort after seven years, 
and it cannot be expected that all participants from inclusion are willing to participate again. 
The choice of timepoint for follow-up, seven years, was due to external circumstances. 
However, considering the chronic course of SLE, all follow-up is valuable for understanding 
the impact of the disease. 
All of the self-assessment questionnaires used in this thesis are generic and not all have been 
tested for validity and reliability in the context of patients with SLE. However, the 
questionnaires are frequently used in research on patients with SLE and in different 
rheumatology settings, and thereby allow for comparison between different studies and 
cohorts of patients with SLE and other rheumatological diseases. Further, the generic nature 
of the questionnaires allows for comparison with patients with diseases other than those 
within rheumatology (20, 28, 95, 114). However, the SF-36 has previously been tested for 
reliability and validity in patients with SLE (65, 92-94) and in Swedish populations (90, 91). 
53
 
 53 
Further, SLE is considered a relatively uncommon disease and testing reliability and validity 
of questionnaires for patients with SLE fell outside the scope of our present studies. 
There are both advantages and disadvantages of using VAS in measuring pain intensity. 
Among the advantages is it is simple to implement, which is the reason it is frequently used 
in clinical practice; VAS was therefore familiar to most of the study participants in the studies 
presented in this thesis. The division of the patients into subgroups using scored pain intensity 
on VAS was considered useful to demonstrate the heterogenous nature of SLE. The 
differences in a cohort population with SLE would not otherwise be detected nor would the 
similarities to the controls from the general population. Cut-off values have been used earlier 
in a study by Burgos et al (28), in which the median of VAS pain was used as a cut-off value. 
They found, as we did in our studies, that a higher pain score corresponded with a higher 
fatigue score. However, the cut-off value creates a border for values close to the cut-off value. 
For example, scoring 38 or 43 mm on VAS may not have any clinical implication. The cut-
off value should therefore be considered as a research tool for highlighting a topic.  
One disadvantage with VAS is its one-dimensional nature, and the challenge mainly consists 
of transforming a subjective experience into one single measurement. To meet this challenge, 
SF-MPQ was used to provide additional and more detailed information on pain. The 
descriptive words used by the patients in the SF-MPQ displayed a picture of the patients’ 
experiences which were later expanded through the narratives in study IV. In addition, SF-
MPQ is preferred for use with patients with longstanding pain (84). However, a score on 
VAS was judged to be more convenient when dividing the patients into two groups at year 0 
for further comparisons. Moreover, the additional patient-reported measurements regarding 
HRQoL, fatigue, anxiety and depression contributed to the multidimensional perspective of 
pain. 
The SF-36 was chosen to measure health, and since SF-36 has been developed to measure 
HRQoL, uncertainty could arise concerning the concepts used in this thesis. For clarification, 
SF-36 was considered appropriate to use since the attributes in the definition of health by the 
WHO, physical, mental and social well-being, are represented in the measurement. 
The questionnaires were completed at the clinic in conjunction with the visit in the SLEVIC 
study, both at year 0 and year 7. This procedure enabled the study participants to ask 
questions if needed and resulted in few missing data. Despite this, some data were missing. 
Issues regarding missing data of descriptive words in SF-MPQ, were resolved through 
dialogue with Professor Ronald Melzack who constructed the measurement (86). The advice 
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from Professor Melzack was to first determine whether the missing values were meant to be 
zero (no pain) based on the patient’s other replies. If it was suspected that the reply was not 
zero (no pain), we took the average of the other descriptors, and added this to the incomplete 
subtotal. 
In a recent study, a moderate-to-good correlation was found between SLAM/SLAM-no lab 
and a Swedish version of the self-reported Systemic Lupus Activity Questionnaire (SLAQ) 
(130). The results from that study may indicate that the discrepancy found in this thesis 
between the patients’ and the physicians’ assessment of disease activity, at least partly, 
depends on which method or assessments are used. In addition, the physicians’ assessment of 
disease activity on VAS has earlier been criticized as being too blunt (131). 
Disease activity, at year 0, measured by SLAM and SLEDAI included laboratory parameters 
lymphocytes, ds-DNA and complements. However, at year 7, these laboratory parameters 
were not included. Therefore, it cannot be excluded that comparison of disease activity 
between year 0 and year 7 would have yielded different results if the laboratory parameters 
had been included for both years. To address this, SLAM and SLEDAI at year 0 were also 
converted to SLAM without lymphocytes (SLAM-no lab) and SLEDAI without ds-DNA and 
complements (SLEDAI-no lab) for appropriate comparison. 
To increase the reliability of the results in the interview study, the context for the study was 
described, and the use of a coding scheme made it possible to follow the different steps in the 
analysis process. Discussions were held between the authors until agreement was reached to 
overcome the subjectivity of the interpretation in the different stages of the analysis process. 
Further, the quotes illustrated and created links between the text data and the resulting 
categories and subcategories (108, 111). There are advantages and disadvantages of 
individual interviews compared to focus group interviews. One advantage is privacy where 
the informants may express feelings and opinions without being scrutinized or inhibited by 
others. A disadvantage may be a feeling of being overlooked by the interviewer and not being 
able to share inspiration and new perspectives from other members of a group.
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12 CLINICAL IMPLICATIONS 
The results from the studies in this thesis clearly point out the heterogenous nature of SLE 
and the importance of assessing patient-reported outcomes to trace patients with a high 
symptom burden like pain, regardless of disease activity. Further, the patient subgroups in 
which pain is present to a varying extent claim that individual adapted interventions and 
support will help patients to better deal with pain and will improve health. Differences in the 
assessment of disease activity by patients and healthcare providers indicated different 
perspectives and focus. This should be taken into account in communication between patients 
and healthcare providers to avoid patients feeling that they are not being taken seriously. The 
healthcare providers should facilitate the patients’ understanding of the various causes which 
could underlie pain in SLE, and thereby enable them to better deal with pain. Further, 
acknowledging the patient’s symptoms and experiences is an obvious and fundamental 
obligation for healthcare providers which will avoid adding to an already existing symptom 
burden.  
Measuring pain as well as other patient-reported outcomes in clinical practice can be used as 
a basis for discussion between the patient and the healthcare provider, and enable self-
reported outcomes to be put in context. In cases of high pain intensity and low disease 
activity (as judged by the healthcare provider), it is crucial to delineate the cause of pain. 
Even if the cause is not fully understood, it is important to provide the patient with available 
facts and alternative explanations. This will help the patient who feels uncertain and 
misunderstood and who is not adhering to medication. For example, when there are no 
objective signs of disease activity, but long-standing generalized pain like central 
sensitization is suspected, it is important to inform and involve the patient, something which 
in itself is considered to be an intervention (43). 
Organizational and structural barriers between the various disciplines in the healthcare system 
may also prevent patients with SLE and pain from receiving appropriate care. Even though 
there are many positive consequences when patients participate in their own care, it cannot be 
assumed that the patients themselves will act as messengers between the various disciplines 
and healthcare providers. Therefore, networks should be developed between the disciplines 
and professions to create multidisciplinary care based on current knowledge and evidence. 
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13 SUMMARY AND CONCLUSIONS 
As far as we know, few studies have been conducted in which SLE-related pain constitutes 
the main focus, and in which HRQoL, fatigue, anxiety and depression have been investigated 
based on the degree of pain. The approach using identification of patients into subgroups by 
pain intensity score clearly demonstrates that patients with SLE are a heterogenous group in 
regard to pain. Earlier studies have shown that patients with SLE, in general, report more 
pain, a poorer HRQoL, a higher level of fatigue, and more anxiety and depression compared 
to the general population. However, the results from this thesis add to the current base of 
knowledge by showing that subgroups of patients with SLE have different symptom burdens, 
and that disease-related pain appears to be an important promotor of poorer HRQoL and 
exacerbation of fatigue. The patients with a high degree of pain also expressed a high impact 
of pain on daily life. They depicted difficulties with performance of practical activities, 
maintenance of their different roles and relationships with family and others. In contrast, 
patients with a low degree of pain did not deviate from the general population in any 
significant way. Anxiety and depression seemed to be least affected by pain. Furthermore, the 
results from this thesis showed that decreased pain was followed by improvement in HRQoL 
and fatigue as well as less anxiety and depression. The results also revealed a discrepancy in 
estimated disease activity by the patients and the physicians. The largest discrepancy was 
found in the patients with high pain intensity which could potentially create communication 
barriers. In addition, the patients with a high level of disease-related pain felt that, because of 
the invisible nature of the pain, the healthcare providers were sceptical to their complaints. 
They also perceived themselves to be messengers in their own care. 
These results highlight the great importance of paying attention to pain in patients with SLE 
in clinical practice, and to develop interventions aimed to alleviate pain and to support the 
patients in dealing with pain. 
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14 SUGGESTIONS FOR FUTURE RESEARCH 
Despite advances in neuroscience and new insights and knowledge on central and peripheral 
pain processing, many areas remain unclear on persistent pain in SLE and other 
rheumatology diseases, not least how to treat them. Taking into account the high symptom 
burden and poorer health associated with pain in SLE as well as the chronic course of the 
disease, future intervention studies aimed to support patients with SLE to better deal with 
pain appear to be of great importance. Proposals for future research areas include healthcare 
providers as well as patients, and when appropriate, significant others: 
x multidisciplinary interventions and educational programmes for patients with SLE to 
help the patients better deal with pain 
x rehabilitation interventions to diminish the impact of pain on working life and 
subsequent economic consequences 
x interventions to increase and strengthen patients´ involvement in healthcare 
x implementation of tools to evaluate patients´ satisfaction with healthcare 
x adaption and implementation of appropriate disease activity indices for SLE in order 
to improve the communication on disease activity between patients and healthcare 
providers  
x educational interventions for healthcare providers about pain and related symptoms 
x educational interventions for healthcare providers about ethical approaches and 
response to the needs of patients with pain. 
Further research close to clinical settings emerge as crucial. Patients with SLE and pain 
should be invited to participate in clinical research as a part of their treatment. Hopefully this 
would signal that pain is a symptom that deserves attention in the healthcare system and 
would give hope for the future. 
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15 SVENSK SAMMANFATTNING 
Bakgrund 
Att insjukna i en sjukdom med ett kroniskt förlopp innebär för de flesta människor 
utmaningar att förhålla sig till. Systemisk lupus erythematosus (SLE) är en autoimmun 
reumatologisk sjukdom som anses vara kronisk, dvs. en sjukdom där det i nuläget inte finns 
någon botande behandling men där det finns möjlighet att med läkemedel minska 
sjukdomsaktiviteten och därmed symptomen. Sjukdomen förlöper vanligen i oförutsedda 
skov, där perioder av låg sjukdomsaktivitet avlöses av perioder med högre sjukdomsaktivitet. 
I princip kan alla organ i kroppen drabbas och ge upphov till organspecifika symptom men 
det förekommer också allmänna symptom som feber, sjukdomskänsla och trötthet. 
Sjukdomens allvarlighetsgrad varierar stort mellan olika individer, från att vara en mycket 
mild till att vara en allvarlig sjukdom. Generellt anses patienter med SLE uppleva mer 
smärta, sämre hälsorelaterad livskvalitet, mer trötthet, oro och nedstämdhet jämfört med 
befolkningen i övrigt. Olika symptom kan också påverka varandra, till exempel kan smärta 
och trötthet förstärka varandra. De beskrivna symptomen och det kroniska förloppet på 
sjukdomen innebär att patienter med SLE löper risk för försämrad hälsa och begränsningar i 
vardagslivet.  
I denna avhandling fokuseras huvudsakligen på SLE-relaterad smärta och hur smärtan 
påverkar hälsan. Begreppet hälsa definieras i enlighet med WHO:s definition att hälsa är ett 
tillstånd av fullständigt fysiskt, mentalt och socialt välbefinnande, inte endast frånvaro av 
sjukdom och funktionsnedsättning…Hälsa i förhållande till upplevd livskvalitet benämns här 
som hälsorelaterad livskvalitet. 
Trots att framsteg har gjorts inom det medicinska omhändertagandet av patienter med SLE, 
så visar studier att patienter med SLE fortsätter att rapportera smärta och sämre hälsorelaterad 
livskvalitet än befolkningen i övrigt. Därtill finns det studier som visar att patienter med SLE 
upplever att vårdgivare inte uppmärksammar smärta vid SLE i tillräckligt hög grad. 
Sammantaget gör detta att mer detaljerad kunskap behövs om i vilken omfattning patienter 
med SLE rapporterar smärta, dess karaktär och hur smärtan förhåller sig till hälso-relaterad 
livskvalitet och andra subjektiva symptom. 
 
Syfte 
Det övergripande syftet med denna avhandling var att undersöka i vilken omfattning patienter 
med SLE rapporterar sjukdomsrelaterad smärta och hur smärtan påverkar hälsan och olika 
aspekter i vardagslivet. 
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I delarbete 1 var syftet att undersöka intensiteten och karaktären på den smärta som patienten 
själv relaterar till SLE samt hur sjukdomsaktiviteten och sjukdomsdurationen förhåller sig till 
smärtan. 
I delarbete 2 var syftet att undersöka intensiteten av all slags smärta, hälso-relaterad 
livskvalitet, trötthet, oro och nedstämdhet hos patienter med SLE och jämföra med ålders- 
och könsmatchade kontrollpersoner från befolkningen. 
I delarbete 3 var syftet att undersöka intensiteten av SLE-relaterad smärta efter sju år, 
förekomst av långvarig utbredd smärta, hälso-relaterad livskvalitet, trötthet samt oro och 
nedstämdhet. 
I delarbete 4 var syftet att undersöka hur SLE-relaterad smärta påverkar patienternas vardag 
samt vilket stöd patienterna ansåg sig behöva från vårdgivare för att bättre hantera smärtan. 
 
Deltagare och metod 
Vid den första datainsamlingen (år 0), som utgörs av delarbete 1 och 2, deltog 84 patienter 
med SLE och 91 köns- och åldersmatchade kontrollpersoner slumpvis utvalda från 
befolkningen. Deltagarna rekryterades från en större pågående studie, SLEVIC (SLE 
Vascular Impact Cohort), där hjärt- och kärlsjukdomar hos patienter med SLE undersöktes. 
Deltagarna fick fylla i självskattningsformulär om hur intensiv de upplevde att smärtan varit 
under den senaste veckan och om hur de upplevde hälso-relaterad livskvalitet, trötthet, oro 
och nedstämdhet.  
De självskattningsformulär som användes var: 
Visuell Analog Skala (VAS) användes för att mäta intensiteten av SLE-relaterad smärta under 
den senaste veckan. Skalan består av en 100 mm lång horisontell linje med två ändpunkter: 
“ingen smärta” och “värsta tänkbara smärta”. Studiedeltagarna fick markera den upplevda 
smärtan med ett lodrätt streck över den horisontella linjen. 
Short-Form McGill Pain Questionnaire (SF-MPQ) användes för att mäta intensiteten och 
karaktären på smärtan den senaste veckan utifrån 15 fördefinierade beskrivande ord. 
Formuläret innehåller även en VAS-skala där deltagarna fick skatta sin aktuella smärta samt 
ett avsnitt där deltagarna fick beskriva sin nuvarande smärta utifrån fördefinierade 
beskrivande ord. 
Medical Outcomes Survey-Short Form 36 (SF-36) användes för att mäta hälso-relaterad 
livskvalitet. Formuläret består av 36 frågor där svaren sammanställs i åtta dimensioner av 
hälso-relaterad livskvalitet. 
Multidimensional Assessment of Fatigue (MAF) användes för att mäta trötthet under den 
senaste veckan. Formuläret mäter trötthet utifrån fyra dimensioner: svårighetsgrad, graden av 
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problem, graden av påverkan på det dagliga livet och tidsperspektivet. 
Hospital Anxiety and Depression Scale (HADS) användes för att mäta symptom på oro och 
nedstämdhet. Formuläret består av 14 frågor, där sju frågor sammanställs till ett index för oro 
och de andra sju frågorna till ett index för nedstämdhet. 
Dessutom insamlades data om ålder, sjukdomsduration, sjukdomsaktivitet (SLAM och 
SLEDAI), SLE skadeindex (SLICC) samt behandling med kortison. 
Vid sju-års-uppföljningen (år 7), som utgörs av delarbete 3, deltog 64 patienter med SLE och 
68 kontrollpersoner från samma grupp av deltagare som medverkade år 0. I denna sju-års-
uppföljning insamlades data som vid år 0 och deltagarna fick återigen fylla i samma 
självskattningsformulär. Som tillägg vid år 7 fick deltagarna på en VAS-skala (100 mm) 
skatta graden av problem som smärtan förorsakat, samt hur länge smärtan hade förekommit. 
Om smärtan varit närvarande mer än tre månader fick deltagarna också markera på en 
kroppsschablon vilka kroppsdelar som gjorde ont  
I delarbete 4 blev 20 patienter med SLE och sjukdomsrelaterad smärta intervjuade om hur de 
upplevde smärtan, hur den påverkade deras vardagsliv och vilket stöd från vårdgivare som de 
ansåg sig behöva för att bättre hantera smärtan. Intervjuerna genomfördes individuellt med 
hjälp av en intervjuguide och spelades in. De inspelade intervjuerna transkriberades ordagrant 
och texten analyserades med kvalitativ innehållsanalys. 
Samtliga delarbeten i denna avhandling har blivit godkända av den regionala 
etikprövningsnämnden i Stockholm. Samtliga deltagare lämnade skriftligt informerat 
samtycke till deltagandet. 
 
Resultat 
Vid analysen av rapporterad smärtintensitet på VAS år 0 kunde patienterna delas in i två 
grupper som skilde sig signifikant från varandra i rapporterad smärtintensitet på VAS: 
patienter som rapporterade låg grad av smärta, <40 mm på VAS, (64 st) och patienter som 
rapporterade hög grad av smärta, ≥40 mm på VAS, 24% (20 st). Patienterna med hög grad av 
smärta karaktäriserades av högre sjukdomsaktivitet och kortare sjukdomsduration jämfört 
med patienterna med låg grad av smärta. I delarbete 2 rapporterade patienterna med hög grad 
av smärta sämre hälso-relaterad livskvalitet, mer trötthet, oro och nedstämdhet. Patienterna 
med låg grad av smärta skilde sig inte signifikant från kontrollpersonerna beträffande smärta, 
i dimensionerna fysisk roll, kroppslig smärta, känslomässig roll och mental hälsa i SF-36 
(hälso-relaterad livskvalitet) samt beträffande trötthet, oro och nedstämdhet. 
Vid år 7 bibehölls gruppindelningen av patienterna som gjordes utifrån rapporterad 
smärtintensitet vid år 0. Det innebar att vid år 7 ingick 50 patienter i gruppen med låg grad av 
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smärta och 14 patienter med hög grad av smärta. De patienter som rapporterade låg grad av 
smärta vid år 0, rapporterade statistiskt oförändrad smärtintensitet, oförändrad hälso-relaterad 
livskvalitet (förutom i dimensionen fysisk funktion) samt oförändrad skattning av trötthet, oro 
och nedstämdhet vid år 7. Patienterna med hög grad av smärta vid år 0 skattade signifikant 
lägre grad av smärta vid år 7. Dock visade det sig att det bara var hälften (sju patienter) som 
hade uppnått en tydlig förbättring medan resterande sju patienter skattade statistiskt 
oförändrad smärtintensitet. Patienterna med minskad smärta skattade även signifikant bättre 
hälso-relaterad livskvalitet samt mindre trötthet, oro och nedstämdhet. Omvänt skattade 
patienterna med kvarstående hög grad av smärta oförändrad och sämre hälso-relaterad 
livskvalitet, mer trötthet, oro och nedstämdhet jämfört med de övriga patienterna och 
kontrollpersonerna. Samtliga patienter med kvarvarande hög grad av smärta rapporterade 
långvarig utbredd smärta. 
I delarbete 4 berättade informanterna om smärtan som de själva relaterade till SLE, även om 
de ibland blev osäkra på orsaken till smärtan. De beskrev smärtan som långvarig och ständigt 
närvarande men på olika ställen. Smärtan och tröttheten var beroende av varandra och 
förstärkte varandra. Många känslor, framförallt frustration, ilska och sorg triggades av 
smärtan. Smärtan väckte också existentiella tankar om hur och varför livet med smärta hade 
blivit som det blev. Mer eller mindre hade informanterna funnit en acceptans och försökte 
anpassa sig till sjukdomen och smärtan. Att vara sjuk betraktades av informanterna som något 
annat än SLE, t.ex. som en influensa eller en förkylning. 
Smärtan var ett hinder för informanterna att vara fysiskt aktiva i den utsträckning som de ville 
och att utföra praktiska sysslor i det dagliga livet. Dessutom påverkade smärtan även 
relationerna till andra och kunde försvåra för informanterna att bibehålla sina olika roller. 
För att hantera smärtan använde informanterna sina inre resurser som t.ex. viljestyrka, 
envishet och anpassning. Även praktiska handlingar, fysisk aktivitet, hjälpmedel och 
läkemedel användes, men trots deras försök att lindra smärtan medförde detta sällan 
fullständig smärtfrihet. 
Trots smärtans negativa påverkan kunde informanterna berätta om att deras erfarenheter av 
smärta hade bidragit till självutveckling såsom inre styrka, att uppskatta andra och nya 
aspekter i livet samt en ökad förståelse för andras svårigheter. 
Informanterna berättade om sina erfarenheter av bra och empatiskt bemötande i vården men 
också om dåligt bemötande och misstroende från vårdgivare. Berättelserna betonade att ett 
gott bemötande och bekräftelse av smärtan från vårdgivare var av avgörande betydelse för 
hur informanterna upplevde stödet från vården. Individuellt anpassat stöd, kunskap och 
information om SLE och smärta efterfrågades från vården liksom god tillgänglighet genom 
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alternativa kommunikationsvägar. Behovet av strukturella och organisatoriska förändringar 
lyftes av informanterna för att de själva inte skulle vara en budbärare i den egna vården. 
Förhoppningar fanns om att olika åtgärder och behandlingar liksom behövliga hjälpmedel 
inte skulle vara beroende av den enskildes ekonomiska situation. 
Konklusion  
Resultaten från dessa studier visar att patienter med SLE inte är en enhetlig grupp beträffande 
sjukdomsrelaterad smärta utan att smärtan förekommer i olika utsträckning hos olika 
individer och över tid. Majoriteten av patienterna rapporterade låg grad av smärta och skilde 
sig inte i någon högre grad från befolkningen i övrigt beträffande hälso-relaterad livskvalitet, 
trötthet, oro och nedstämdhet. Dock, den mindre andel av patienterna som hade hög grad av 
smärta rapporterade avsevärt försämrad hälso-relaterad livskvalitet, mer trötthet och större 
hinder i det dagliga livet. Trots låg sjukdomsaktivitet och frånvaro av allvarliga 
organengagemang är därför smärta ett viktigt symptom att uppmärksamma i vården av 
patienter med SLE. Förutom farmakologisk smärtlindrande behandling är få andra 
interventioner tillgängliga för att lindra smärtproblem hos patienter med SLE. Det behövs 
därför fortsatt forskning om olika interventioner för att lindra smärtan och stödja patienten. 
Nätverk mellan olika professioner och vårdgivare bör också utvecklas för att patienter med 
smärta inte själva ska behöva vara budbärare i sin egen vård.  
Dock kan mycket göras med nuvarande kunskap och organisation. Att bemöta patienten med 
respekt och att bekräfta patientens upplevelse av smärta är en förutsättning för att patienter 
med SLE-relaterad smärta ska uppleva stöd i vården. 
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